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ABSTRACT 
The crystal structures of Rhizomucor miehei as partic proteinase (RMP) 
and its pepstatin A complex have been determined at 2.15 A and 2.7 A, 
respectively. The structure of the native enzyme was refined to a 
crystallographic R-factor of 21.5% (R-free = 28.1 Oh). RMP contains two 
domains that consist predominantly of psheets. A large substrate binding 
cleft is clearly visible between the two domains, and the two catalytic residues 
Asp38 and Asp237 are located in the middle of the cleft with a water molecule 
bridging the carboxyl groups of Asp38 and Asp237. It is proposed that the 
optimal pH of each aspartic proteinase is determined by the electrostatic 
potential at the active site, which, in turn, is determined by the positions and 
orientations of all the residues near the active site. RMP is the most 
glycosylated and most thermally stable among the aspartic proteinases. It is 
proposed that the highly flexible carbohydrates act as heat reservoirs to 
stabilize the conformation of RMP and thereby provide the enzyme with high 
thermal stability. Three-dimensional structural and sequence alignments of 
RMP with other aspartic proteinases suggest that RMP and Mucor pusillus 
aspartic proteinase (MPP) diverged from the main stream of aspartic 
proteinases at an early stage of evolution. 
The structure of the RMP-pepstatin A complex was refined to a 
crystallographic R-value of 19.3% (R-free = 28.0%). In the final model, a 
pepstatin A molecule fits into the large substrate-binding cleft between the two 
domains of RMP in an extended conformation up to the alanine residue at the 
P2' position. The statine residue at the "P3'-P4'" position forms an inverse 
y-turn (P3'-PI '), with its leucyl side chain binding into the S1' subsite. The 
inhibitor interacts with the residues of the substrate binding pocket by either 
hydrogen bonds or hydrophobic interactions, or both. 
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Chapter 1. lntroduction 
1 .I An overview 
Aspartic proteinases (EC 3.4.23) are a group of proteolytic enzymes, 
which are usually optimally active at acidic pH (except renins). They are so 
called because of the presence of two catalytically-essential aspartic acid 
residues at the active site. Aspartic proteinases, together with serine, 
cysteine and metalloproteinases, form four major classes of proteolytic 
enzymes. Aspartic proteinases are widely distributed, having been found in 
micro-organisms, plants and mammals. Because they cleave peptide bonds, 
aspartic proteinases play important roles in many biological processes. These 
enzymes are usually inhibited by pepstatin, a pentapeptide produced by 
Streptomyces (Umezawa et a/., 1970). The chemical structure of the 
pepstatin molecule is shown in Figure 1 . I .  It contains two dipeptide analogue 
statine (STA) residues and one isovaleric acid (IVA) residue. This molecule is 
usually called pepstatin A, while its derivatives formed by replacing isovaleryl 
with n-caproyl and iso-caproyl are called pepstatin B and pepstatin C. The 
aspartic proteinases are broadly divided into two main groups: pepsin-like and 
retroviral enzymes. The pepsin-like enzymes can be further divided into the 
rVA Val 
CH3 CH3 CHj CH3 
Val STA ST A 
Figure 1.1. Chemical structure of pepstatin (Umszawa et a/., 1970). IVA 
represents isovaleric acid and STA represents statine. 
following groups: pepsins and chymosins, cathepsins, renins and fungal 
aspartic proteinases (Szecsi, 1992). The pepsin-like aspartic proteinases are 
monomers and have molecular weights of approximately 35 - 38 kDa. These 
enzymes contain between 320 and 361 amino acid residues, and consist of 
two domains of approximately the same size. The two domains are related by 
an approximate 2-fold symmetry (Tang et a/., 1978). The two catalytic 
aspartate residues are contributed by each of the two domains, respectively. 
The retroviral aspartic proteinases have between 99 and 150 amino acid 
residues, existing as homodimers in the active fonn. With the discovery that 
HIV proteinase is a retroviral aspartic proteinase, aspartic proteinase studies 
have become a very important area in the structure-based drughnhibitor 
design research. 
Because of their digestive characteristics, many aspartic proteinases 
have been used as milk-clotting enzymes in cheese industry. These enzymes 
can cleave wasein in milk into two parts: a para-K- portion and a 
macropeptide. This cleavage disturbs the stability of the casein micelles and 
causes the aggregation of the proteins, forming a curd. The most prominent 
milk-clotting enzyme is chymosin, which is usually obtained from the stomach 
of young calves. Chymosin, a pepsin-like aspartic proteinase, has been used 
in cheese making since antiquity. Two types of chymosins, A and B, are 
present naturally. These two types of chymosins differ by a single amino acid 
residue at position 244 in their amino acid sequences. Residue 244 is an 
aspartate in chymosin A and a glycine in chymosin B. Chymosin possesses 
high milk-clotting activity due to its specific cleavage of  casein (Brown & 
Ernstrom, 1988). Chymosin is the enzyme of choice and the standard against 
which all the other aspartic proteinases are measured. However, due to a 
worldwide shortage of calf chymosin. attempts are being made to find 
substitutes for this enzyme. One of the substitutes is Rhizomucor miehei 
aspartic proteinase (RMP, EC 3.4.23.23). It exhibits high milk-clotting activity 
along with low proteolytic activity compared with other aspartic proteinases 
(Yada & Nakai, 1986a,b). RMP has been used to make excellent quality 
Cheddar cheese (Prins & Nielsen, 1970). However, it is the most thermally 
stable enzyme among the aspartic proteinases (Hyslop et a!.. 1979), and 
therefore is of limited use as a milk coagulant. The high thermal stability 
results in the survival of the enzyme activity after cooking of the curd and thus 
may cause ill flavor in cheese during long maturating periods (Yamashita 
et al., 1994). The X-ray crystallographic study of RMP was carried out in 
order to determine the reason for its high thermal stability and provide a 
guideline for further modification of this enzyme to reduce its thermal stability 
in order to try to make use of its milk-clotting activity. 
1.2 The making of cheese 
Cheese making is perhaps one of the oldest means of preserving food. 
Cheese is the generic name of a group of products cultured/ferrnented from 
milk. The first cheese was believed to be made in the Tigris-Euphrates Valley 
about 8000 years ago in what is now Iraq (Holsinger et a/., 1995). Nowadays 
approximately 4000 different cheese varieties, with a variety of flavor andlor 
texture characteristics, are produced worldwide (Steele, 1995). The ability to 
manufacture such a variety of products from milk is due to the different 
conditions and microorganisms used in the manufacturing. 
1.2.1 The composition of milk 
Milk is the liquid food secreted by all species of mammals to supply 
their young with nutrition and immunological protection. The composition of 
milk has been reviewed by Johnson (1974) and Jenness (1988). It is an 
extremely complex mixture of components, consisting of water, lipids, 
carbohydrates, proteins, salts, and many miscellaneous compounds. It 
contains probably about 10' different kinds of molecules. 
The largest component in milk is water, which can be up to 87% 
(Johnson, 1974). All the other components in milk are either dissolved or 
suspended in water. A small percentage of the water is hydrated to lactose 
and salts, or is bound to proteins. The lipids, which are usually called "fat", 
are 98% triglycerides, mostly as globules with diameters of 0.1 to 1.5 pm. 
Carbohydrate is present mainly as lactose. There are several classes of 
proteins. The largest group (approximate 80% are phosphoproteins called 
"caseins". They are associated with calcium in the casein micelles, which are 
20-300 pm in diameter (Jenness, 1988). The caseins can be further divided 
into four major groups: a,,-, a*-, P-, and waseins. The other milk proteins 
are called "whey proteins" and include P-lactoglobulin, a-lactalbumin, blood 
serum albumin and immunoglobulins. The ions are mainly Na', K', CaZ+, Mg2+, 
PO,&, CI-, Cot-, SOP- and citrate anion. Besides these compounds, milk 
also contains trace elements, such as aluminum, bromine, copper, zinc, iron, 
manganese, and silicon. 
1.2.2 The procedures involved in cheese making 
The cheese making process can be divided into manufacturing and 
ripening phases. The manufacturing stage refers to those events that occur 
during the first 24 hours (Fox, 1993). The basic steps in the manufacturing 
stage are: acidification; coagulation; dehydration; shaping; and salting 
(Holsinger et a/., 1995). During the ripening stage, the curd undergoes 
significant biochemical changes which are regulated by the moisture content, 
the salt content and the microflora. The differentiation in flavor, odor and 
texture of various cheeses is determined by the biochemical changes during 
this stage. 
Manufacturing stage 
Acidification of cheese milk is the first step in cheese making. It is a 
progressive development of acidity throughout the manufacturing stage. Acid 
production is very important to the quality of cheese. Acidification affects the 
milk coagulant's activity, curd strength, syneresis, pH and growth of non- 
starter microorganisms. If the milk is too acidic, the cheese will be crumbly; if 
too basic, the cheese is pasty and sticky. 
Coagulation 
Coagulation is the second and the most important step in the 
manufacturing stage. The curd is formed in this stage in one of two ways: 
acid or enzymatic coagulation. In acidturd cheeses (cottage, cream), the 
curd is formed by the direct addition of acid to the milk or by lactic acid 
produced by the fermentation of lactose. Nowadays, coagulation by various 
aspartic proteinases has become predominant in cheese-making. Of the 
many aspartic proteinases obtained from animal, plant and microbial sources 
that have been used for the manufacture of cheese and other foods since 
antiquity, the most common one is chymosin. The properties of curds formed 
by this method are quite different from those of the acid precipitated curds. 
These curds have better syneresis properties which make it possible to 
produce low moisture curd without hardening. 
Dehydra tion 
From this point, the post-coagulation changes start. These changes 
will determine the quality of the final products. The curd synereses quickly 
when cut, expelling the whey, although it is quite stable if it is quiescent. The 
syneresis is controlled by quite a few factors: milk composition, CaZ+ 
concentration, pH of the whey, cooking temperature etc. The extent of 
dehydration in this step determines the moisture content of the curd, which will 
affect the odor, flavor and quality of the final cheese products. It is from this 
step that the differentiation of cheeses begins. 
Salting 
Almost all cheese varieties are salted. Salt (NaCI) is added to control 
the water activity, microbial growth and activity, enzyme activity and the 
physical changes in the cheese proteins during the ripening stage. Salting 
affects the flavor and the quality of cheeses. Usually, salting is done by 
immersing the cheese blocks in a brine solution (20-22% NaCl + 0.3% CaCI,) 
at lZ°C, from which the salt diffuses into the cheese (Rosenthal, 1991). 
Ripening stage 
After the manufacturing stage, the cheeses are stored in a ripening 
room from two weeks to several months. The cheese ripening involves 
several biochemical changes. These changes include proteolysis, glycolysis 
and lipolysis. Proteolysis is the most significant process because it results in 
the breakdown of the structural network of casein formed during the 
manufacturing stage and the formation of a soft and smooth mature cheese. 
Flavor compounds produced by proteolysis are released during the ripening 
stage. The major proteolytic changes during maturation of cheese are the 
conversion of protein to large peptides, large peptides to small peptides, and 
small peptides to free amino acids, amides and ammonia (Farkye, 1995). The 
rate and extent of proteolysis in the ripening stage are determined by the 
types and activities of the milk-clotting enzymes, pH value, moisture content 
and salt, chamber temperature and surface treatment during ripening 
(Rosenthal, 1 991 ). Usually less than 1 0% of the milk-clotting activity used for 
cheese making is retained in cheese. The reduction in milk-clotting activity of 
the coagulant enzymes is usually done by heating during the manufacturing 
stage. 
The caseins were defined originally as a group of phosphoproteins 
which precipitate from raw skim milk upon acidification to pH 4.6 at 20°C 
(Whitney et a/., 1976). They make up to 80% of the total proteins in milk. 
With the development of the primary structural studies, caseins are now 
classified according to their chemical structures. Caseins can be divided into 
four major groups, a,,-, cr,-, P-, and K- in the ratio 3:0.8:3:1. These casein 
proteins are associated with calcium in "casein micelles", which are 
20-300 pm in diameter (Jenness, 1988). The outside surface of micelles 
contain a high concentration of ecaseins (Walstra & Jenness, 1984). 
The K-caseins are soluble over a very broad range of calcium ion 
concentrations (Waugh & Von Hippel, 1956). This solubility stabilizes the 
casein micelles (Waugh & Von Hippel, 1956). The K-caseins are the only 
major component of the casein complex which contains carbohydrate and 
occur as a mixture of polymers held together by disulfide bonds. With the 
addition of reducing agents, like mercaptoethanol and dithiothreitol, the 
polymers can be converted completely to monomers. The relatively high 
heterogeneity of caseins is due to the genetic differences, variation in 
carbohydrate content and/or phosphate content and the para-K-portion of the 
molecule. Two genetic variants of the K-caseins are known: A and B 
(Thompson, 1970; Mackinlay & Wake, 1971). Both of these two variants 
show multiple bands in the alkaline urea gel electrophoresis in the presence of 
mercaptoethanol, with the A variant bands migrating faster (Swaisgood. 
1975). The A variant is predominant in most species of domesticated animals 
(Aschaffenburg, 1968). 
The amino acid sequence of the two K-casein variants have been 
determined (Joiles et a/., 1972a, b; Mercier et aL, 1973) (Figure 1.2). Both 
variants contain 169 amino acid residues. The sequence difference between 
these two variants is located at residues 136 and 148. In variant A, residues 
I36 and 148 are threonine and aspartic acid, respectively. In variant B, these 
two residues are isoleucine and alanine, respectively. Among all the caseins, 
the K-caseins are the ones that are most readily cleaved by chyrnosin (Kalan 
& Woychik, 1965). The K-caseins are split by chymosin at the PhelO5- 
Met1 06 bond, producing the cationic para-K-portion of the molecule (residues 
1-1 05) and the anionic macropeptide (residues 1 06-1 69). Splitting of 
n-caseins destroys the stability of the milk system and the caseins begin to 
aggregate, forming a curd. Further proteolysis of K-caseins during the 
ripening will determine the flavor, body and texture development in cheese. 
QEQNQEQPIR CEKDERFFSD KIAKYIPIQY VLSRYPSYGL NYYQQKPVAL '' 
INNQFLPYPY YAKPAAVRSP AQ ILQWQVLS NTVPAKSCQA QPTTMARHPH log 
105~106 
PHLSFMAIPP KKNQDKTEIP TINTIASGEP TSTPTTEAVE STVATLEDSP '" 
I (variant B) A 
EVIESPPEIN TVQVTSTAV 169 
Figure 1.2. Amino acid sequence of variant A of K-casein in the one-letter 
code for amino acids (I UPAC-I UB Commission on Biochemical Nomenclature, 
1972); variant B sequence differences are also denoted. 
1.2.4 Milk-clotting enzymes 
One of the most important steps in cheese making is clotting the milk. 
Although the curd can be formed in several ways, clotting by milk coagulant 
enzymes has become predominant in the modem cheese industry. Many 
proteolytic enzymes will clot milk and milk-clotting enzymes have been 
obtained from all kinds of sources, such as animals, plants, fungi and bacteria. 
To be a good milk-clotting enzyme, the enzyme should possess the following 
characteristics: 
(1 ) High milk-clotting activity due to selective cleavage of  casein. 
(2) Low non-specific proteolytic activity. 
(3) Low thermal stability. 
Milk-clotting enzymes from various sources have been made 
commercially available. Examples of these enzymes are chymosin, porcine 
pepsin, bovine pepsin and chicken pepsin from animals; endothiapepsin, 
Rhizomucor miehei aspartic proteinase (RMP) and Mucor pusillus aspartic 
proteinase (MPP) from fungi; and papain, chymopapain, ficin and bromelain 
from plants. Among these enzymes, calf chymosin is still the ideal enzyme 
and the standard against which other milk-clotting enzymes are compared. 
Because of its relatively high milk-clotting activity, RMP has been used as a 
substitute for calf chymosin and has about a 30% share of the world milk- 
clotting enzyme market. 
1.3 Rhizomucor miehei aspartic proteinase 
Rhizomucor miehei aspartic proteinase (RMP)  is the native enzyme 
form obtained by fermentation of Rhizomucor miehei. RMP was extensively 
studied in the 1970s and 1980s by several groups, Stemberg, Rickert and 
colleagues, and Foltmann and colleagues. RMP is identical to the enzyme 
which is commercially available as Rennilase (Bech & Foltmann. 1981 ; 
Boel et ab, 1986). The enzyme contains 361 amino acid residues and the 
molecular weight is 38.7 kilodaltons. RMP is synthesized as a zymogen 
containing a 47-amino-acid propeptide from a precursor containing 430 amino 
acid residues (Bech & Foltmann, 1981; Boel et a/., 1986; Gray et al., 1986). 
Like many other aspartic proteinases, RMP can also be inhibited by 
pepstatin A, the common aspartic proteinase inhibitor. 
1.3.1 The amino acid sequence of RMP 
The amino acid sequence of RMP was identified from the sequence 
determination of its zyrnogen (Bech & Foltmann, 1981; Boel eta/., 1986; Gray 
et a/., 1986). The amino acid sequence of RMP is shown in Figure 1.3. The 
enzyme is glycosylated at Asn79 and Asn188 (Boel et a/., 1986). Two 
disulfide bonds are present in the molecule, Cys5 1 -Cys57 and Cys272- 
Cys316 (Boel et a/., 1 986). 
AAADGSVDTP GYYDFDLEEY AIPVSIGTPG QDFLLLFDTG SSDWPHKG 
CTKSEGCVGS RFFDPSASST FKATNYNLNI TYGTGGANGL YFEDSIAIGD 'OD 
ITVTKQILAY VDNVRGPTAE QSPNADIFLD GLFGAAYPDN TAMEAEYGST 
YNTVHVNLYK QGLISSPLFS VYMNTNSGTG EWFGGVNNT LLGGDIAYTD '0° 
VMSRYGGWF WDAPVTGITV DGSAAVRFSR PQAFTIDTGT NFFIMPSSAA " O  
SKIVKAALPD ATETQQGWW PCASYQNSKS TISIVMQKSG SSSDTIEISV 'O0 
PVSKMLLPVD QSNETCMFII LPDGGNQYIV GNLFLRFFVN VYDFGNNRIG ' "  
FAPLASAYEN E 36L 
Figure 1.3 The amino acid sequence of RMP using the one-letter code for 
amino acid residues (I UPAC-IUB Commission on Biochemical Nomenclature, 
1972). 
1.3.2 The milk-clotting activity of RMP 
RMP was first reported by Prins and Nielsen (1970) to be used as a 
milk coagulant in making good quality Cheddar cheese. It is quite stable over 
a broad range of conditions, with the maximum stability between pH 4.0 and 
6.0 (Stemberg, 1971). Bond specificity studies with synthetic substrates 
(Sternberg, 1972) show that RMP cleaves peptide bonds which have an 
aromatic amino acid on the carbonyl side of the peptide bond. Like other 
aspartic proteinases, RMP cleaves K-casein at the peptide bond between 
Phe105-Met106. The kinetic study results of RMP and several other aspartic 
proteinases catalyzing the cleavage of a synthetic hexapeptide and K-casein 
(Martin et a/., 1980) show that RMP exhibits maximum activity at a 
temperature above 63% and pH around 4.7, with the synthetic hexapeptide 
Leu-Ser-Phe(N0,)-Nle-Ala-Leu-OMe as the substrate. Nle in this hexapeptide 
sequence refers to norleucine. The site cleaved by RMP in this substrate is 
the peptide bond between Phe(N0,) and Nle. Under the same experiment 
conditions the k,/K, for RMP (41.5 mM"s") is higher than that for chymosin 
(25 to 30 mM%'). This indicates that this hexapeptide is a slightly better 
substrate for RMP than for chymosin. Milk-clotting activity towards K-casein 
for RMP (0.4 pg-') is only 1/6 of that of chymosin (2.5 pg-'). Therefore, the 
milk-clotting activity for RMP is still low compared to that of chymosin. 
1.3.3 The inhibition of RMP by pepstatin A 
The inhibition of RMP by pepstatin A was first reported by Rickert and 
McBride-Warren (1 977). RMP is progressively inhibited by increasing the 
amounts of pepstatin A when incubated at pH 5.0 for 30 minutes at 25°C. 
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Figure 1.4. The progressive inhibition of RMP by pepstatin A. This diagram is 
a redrawing of the original diagram by Rickert & McBride-Warren (1 977) 
The inhibition curve is shown in Figure 1.4. From the inhibition diagram, it is 
obvious that the inhibition of RMP by pepstatin A is not in a 1 :1 ratio. RMP 
quickly loses 70% of its activity as the molar ratio of pepstatin A : RMP 
increases from 0 to about 1 .O. At this rate, the enzyme would be expected to 
be 1 OOoh inhibited at the pepstatin A : RMP molar ratio of 1.5. However, the 
inhibition reaction undergoes a dramatic change after RMP loses 70% activity. 
The residual 30% activity seems to be resistant to pepstatin A's inhibition. 
Therefore, 15 times more pepstatin A is required to eliminate the residual 30% 
activity of RMP, and 100% inhibition is achieved at the pepstatin A : RMP 
molar ratio of 6. This type of inhibition by pepstatin A has also been observed 
in the studies of yeast protease A (Saheki & Holzer, 1975) and kidney renin 
(Miller et a/., 1972). 
Rickert and McBride-Warren (1977) also carried out the studies on the 
conformational change associated with pepstatin A's inhibition by monitoring 
with CD spectroscopy. They observed that there was no major conformational 
change of RMP when the enzyme was incubated with pepstatin A at an 
equimolar amount. The spectrum suggested that there was only a minor 
general "loosening" of the tertiary structure of RMP. When RMP was 
incubated with sufficient amount of pepstatin A to totally inhibit the enzyme, a 
major conformational change was observed. The CD spectrum suggested a 
relaxation of the distorted p-structure predicted for the native RMP structure 
(McBride-Warren & Rickert, 1973). 
Schechter and Berger (1 967) pointed out that the substrate-binding site 
of proteinases could be divided into several subsites, each accommodating 
one amino acid residue of the peptide substrates. These subsites are located 
on both sides of the catalytic site and are named as S1, S2, S3, etc. and Sl', 
S2', S3', etc. (Figure 1.5). The corresponding residues for each of the binding 
subsites in the peptide substratedinhibitors are named as P i ,  P2, P3, etc. 
and Pi', P2', P3', etc. For the inhibitor pepstatin A molecule, the positional 
labels for the residues are shown in Figure 1.6. Because statine is a dipeptide 
analogue, it occupies two positions. The binding subsites in the RMP 
molecule are from S4 to 54'. 
1.3.4 Other characteristics of RMP 
RMP is the most highly glycosylated among the aspartic proteinases, 
possessing about 6% carbohydrate (Rickert & McBride-Warren, 1974). The 
carbohydrates are N-acetyl-D-glucosamine, D-mannose, D-glucose and 
D-galactose at the ratio of 2:7:2:1 (Rickert 8 McBride-Warren, 1974). The 
glycosylation sites of RMP are Asn79 and Asn188, respectively (Boel et a/., 
1986). Both of the carbohydrate-enzyme linkages are type I linkages, i.e., 
N-acetyl-D-glucosamine linked to an asparagine residue within the sequence 
Asn-X-Thr (X is any of the common amino acids) which is called a sequeon 
(Devlin, 1982). Oxidation of RMP with 0.1 M periodate for 5 hours at 0°C 
results in a 40% loss of carbohydrate and no activity loss (McBride-Warren & 
Rickert, 1973). Prolonged oxidation of RMP (up to 48 hours) gives additional 
10% loss in carbohydrate content and 50% decrease of enzyme activity. The 
residual carbohydrate is resistant to further oxidation. A thermal denaturation 
3 3 1  ...- + H 3 ~  P4 P3 p2 PI PI' 
Catalytic site 
ENZYME (Aspartic proteinases) 
Figure 1.5. Schematic representation of the substrate binding site in the 
aspartic proteinases. 
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Figure 1.6. The positional names for the residues in the pepstatin A molecule. 
study (Ledward et a/., 1975) indicated that RMP has maximum stability (77OC) 
at its isoelectric point. Studies by Hyslop et a/. (1979) indicates that RMP is 
the most thenostable aspartic proteinase. This high thermal stability of RMP 
limits its use as a milk coagulant. In 1991, Brown and Yada reported that the 
native RMP was more thermally stable than the partially deglycosylated RMP 
(37.8% less carbohydrate) in heat denaturation studies. This result suggests 
that N-linked carbohydrates on RMP help to provide the enzyme with high 
thermal stability. 
CD spectroscopy shows that RMP consists mainly of p-structures and 
few helical segments (McBride-Warren & Rickert, 1973). CD spectra of the 
oxidized RMP indicates that there are no major conformational changes up to 
5 hours after the exposure to periodate. Decrease of p-structure is observed 
for the prolonged oxidized RMP (24-48 hours). Studies by De Konning & 
Draaisma (1973) and Lagrange et a/. (1980) show that the isoelectric point for 
RMP is 4.58. RMP can be rapidly inhibited at pH 5.0 and 10°C by a 78-fold 
molar excess of diazoacetyl norleucine methyl ester while adding a 78-fold 
molar excess of Cu2' simultaneously (Rickert & McBride-Warren, 1977). This 
indicates that RMP can also inhibited by diazon ium compounds. Denaturation 
of RMP by Gdn-HCI (Brown 8 Yada. 1991) is described as a two-stage model 
where only the native and denatured molecules exist in significant 
concentrations. 
1.4 Aims and objectives 
1.4.1 The structural determination of RMP 
Our understanding of biological function of a protein molecule relies on 
our knowledge of its three-dimensional structure. From the three-dimensional 
structure, precise knowledge of the protein fold, and the conformations of the 
active site, substrate-binding site, regulatory site etc. can be obtained, and the 
reaction mechanism can be proposed if the protein is an enzyme. From the 
structure and proposed reaction mechanism, modifications of the protein 
molecule can be carried out to try to improve the molecule's biological 
activities and remove unwanted side effects. X-ray crystallography is one of 
the major methods in determining three-dimensional structures of proteins. 
Modifications of RMP have been undertaken to try to improve its milk- 
clotting activity and decrease its thermal stability. However, these 
modifications are still in the trial and error stage without the guidance of a 
three dimensional structure. With RMP1s increasing share of the world milk- 
clotting enzyme market (about 3O0/0 now; Harboe, 1 W6), structure-based 
modifications of this enzyme have become a priority. Therefore, the crystal 
st ruct u ra .I determination of RMP was carried out. From the crysta .I structure, 
the active site confonation, substrate-binding type and possible catalytic 
mechanism of RMP can be obtained. The preliminary studies of RMP were 
carried out by Jia et al. (1 995). Jia et a/. (1 995) established the initial 
crystallization conditions of RMP and obtained a preliminary molecular 
replacement solution of RMP with an incomplete 2.8 A data set of poor 
quality, using the coordinates of Mucor pusillus aspartic proteinase (MP P) as 
a search model. In the research project, crystals with better quaiities were 
grown under improved crystallization conditions and a good quality 2.15 A 
synchrotron data set was collected at DESY synchrotron, EMBL, Hamburg. 
From this crystallographic study of RMP, the following questions were also 
expected to be answered in order to provide a guideline for further 
modification of RMP. 
(1) Why is RMP effective as a milk-clotting enzyme? 
(2) Why does RMP have the greatest thermal stability of any milk- 
clotting aspartic proteinase? 
(3) What is the function of the carbohydrate? 
(4) How could RMP be modified to improve its properties? 
(5) What determines the pH optimum for the activity of an aspartic 
proteinase? 
1.4.2 The structural determination of the RMP-pepstatin A complex 
After the crystal structure of RMP was solved, a structural comparison 
study of RMP with other aspartic proteinases was carried out (Yang et a/., 
1997). The comparison results show that RMP and MPP diverged from the 
main stream of aspartic proteinases at an early stage of evolution. They form 
a subfamily of the aspartic proteinases. Since no structures of RMP or MPP 
complexes with inhibitors were published at the time that the native RMP 
structure was solved, a study of the RMP-pepstatin A complex was carried 
out. From the study of the RMP-pepstatin A complex, it was hoped to 
determine whether RMP has any differences in the substrate binding, catalytic 
mechanism or protein folding compared to other as partic proteinases. This 
would improve our knowledge about aspartic proteinases. The results from 
the study of this complex may also provide a guideline for the synthesis of 
new potent aspartic proteinase inhibitors. 
Chapter 2. Introduction to protein crystallography 
The biological functions of a protein molecule are closely related to its 
three-dimensional structure. The three-dimensional structure of protein 
molecules can be determined by several methods, such as protein 
crystallography, macromolecular NMR and electron microscopy. Protein 
crystallography is the application of the techniques of X-ray diffraction to 
protein crystals. During the past thirty years, protein crystallography has 
advanced rapidly with the development of computer science. It has become 
one of the most powerful methods in elucidating the three-dimensional 
structure of proteins. The X-ray analysis of a protein structure usually 
includes the following four steps: crystallization, crystal diffraction and data 
collection, phase determination, and model-building and refinement. This 
chapter is a brief introduction to each of these steps. Most of the information 
provided in this chapter comes from the X-ray protein crystallography 
textbook: Principles of Protein X-ray Crystallography (Drenth, 1 994). The 
following textbooks are also used as references: Protein Crystallography 
(Blundell & Johnson, 1976), Crystal Structure Analysis: A Primer (Glusker & 
Trueblood. 1985) and X-ray Structure Determination: A Practical Guide (Stout 
& Jensen, 1989). As the key step of protein crystallography is to determine 
the phase angle for each reflection, and the molecular replacement method 
(MR) was used to determine the phase angles for RMP, this method will be 
discussed in greater detail. 
2.1 Crystallization of proteins 
Crystals are formed by the three-dimensional periodic repeat of a 
building block. This building block is called a unit cell. The unit cell is 
characterized by six parameters: three axial lengths: a, b, and c; and three 
interaxial angles a, P, and y. According to these six parameters, the crystals 
are divided into seven crystal systems (Table 2.1). A unit cell contains one or 
more molecules related by crystallographic symmetries which can be defined 
by space groups. A space group is a group of symmetry operations 
consistent with an infinitely extended, regularly repeating pattern. There are a 
total of 230 space groups. Because they are chiral molecules, proteins can 
crystallize only in space groups that have only rotational andlor translational 
symmetry elements. The most common space group found for proteins is 
P2,2,2,. 
Compared to X-ray protein crystallography, protein crystallization is an 
underdeveloped area and is still at a trial-and-error stage. Crystallization 
databases, screens and robots have been developed. However, the 
determination of optimum crystallization conditions for proteins is still a matter 
Table 2.1. The seven crystal systems. 
Crystal Number of Parameters Reciprocal 
system independent lattice 
parameters symmetry 
6 - Triclinic a t b # c ,  a r p # y  1 
Monoclinic 4 a t  b #  c; a= y=90° ;p>900  2/m 
Orthorhombic 3 a # b # c ;  a = p =  y=90°; rnmm 
Tetragonal 2 a = b # c ;  a = p =  y=90° 4lmmm 
Trigonal 
hexagonal 2 a = b # c ;  a = p = 9 0 ° ;  y= 120" 6Immm 
Hexagonal 2 a = b + c ;  a=p=90° ;y=1200  61mmm 
of trial and error. The crystallization of proteins usually involves four important 
steps (Drenth, 1 994): 
( 1 )  Determination of the purity of the protein. Usually the purer the 
protein, the better the chances to grow crystals. 
(2) The protein is dissolved in a suitable solvent from which the protein 
crystal is grown. Usually the solvent is a water-buffer solution, 
sometimes with an organic solvent such as 2-methyl-2,4- 
pentanediol (MPD) added. Normally, the precipitant is also added 
to an extent that it does not cause precipitation of the protein. 
(3) The protein solution is equilibrated with the precipitant solution to 
reach a supersaturation stage. Spontaneous formation of nuclei is 
achieved at this high supersaturation state. 
(4) Once the nuclei are formed, protein crystals start to grow. 
To achieve crystal growth, supersaturation should be kept at a lower 
level so that only a few nuclei are formed. Crystals should grow slowly to 
reach a maximum degree of order in their structure. Although many 
techniques have been developed for protein crystallization, they fall into one 
of the following four major categories: 
(1) Batch crystallization. The precipitating reagent is added to the 
protein solution to raise the protein solution to a high 
supersaturation state, from which the crystals may grow. 
(2) Liquid-liquid diffusion. In this method the protein solution and the 
solution containing the precipitant are layered on top of each other 
in a small-pore capillary tube. The solution with a higher density is 
at the bottom. 
(3) Vapor diffusion method. This is the most common method. In this 
method. the  pmtein solution is equilibrated with the precipitating 
solution through the vapor phase. The protein concentration is 
slowly increased to a supersaturation state. This technique can be 
divided into three methods: hanging drop method, sitting drop 
method and sandwich-drop method. 
(4) Dialysis. In this method, the protein solution is dialyzed against the 
precipitating solution to achieve nuclei formation and crystal growth. 
The advantage of this method is that one can change the 
precipitating solution readily. 
2.2 Data collection and data processing 
X-rays were discovered by German physicist Wilhelm C. Roentgen in 
1895. The diffraction of X-rays by crystals was discovered by Max von Laue 
in 1912. He described the diffraction from a crystal as diffraction from a three- 
dimensional grating. In the same year, W. L. Bragg, the father of modem 
crystallography, noticed the similarity of diffraction to ordinary reflection 
(Figure 2.1) and deduced a simple equation (Bragg's law) treating the 
diffraction as "reflection" from planes in the lattice. 
where n is an integer, h is the wavelength of the X-ray radiation used, dr,kr is 
the perpendicular distance between adjacent lattice planes determined by the 
Miller indices M, and 8jd1 is one half of the angle between the incident and 
diffracted X-ray beams for reflections from these planes. 
The intensities i(hkl)s of the reflections can be measured by several 
ways: single photon scintillation counters, photographic films, image plates 
and area detectors. For protein crystallography, the intensities of reflections 
Figure 2.1. Construction showing Bragg's law for diffraction. PI and Pz are a 
pair of reflection planes with interplanar spacing dul. 1 and 2 are the parallel 
incident beams which make an angle Q M I  with the reflection planes.1' and 2' 
are the diffracted beams. O'A + O'B is the path length difference between 
beams I ' and 2', which is equal to 2dhkl sineMI 
are usually measured by the last two methods. Image plates are plates 
covered with a thin layer of inorganic storage phosphor. When exposed to X- 
rays, the X-ray photons excite electrons in the phosphor to higher energy 
states. Part of this energy is emitted very quickly as fluorescence light in the 
visible wavelength region. However, a significant amount of energy is stored 
in the colour centers of the phosphor for a period of several days, and is 
slowly released. On illumination with strong white light, the energy trapped in 
the colour centers is released very quickly. In practical applications, the 
image plates are scanned with a red laser and the emitted blue light is 
measured with a photomultiplier. The light emitted is usually proportional to 
the number of photons to which that particular region of the plate was 
exposed. Area detectors are electronic devices that detect X-ray photons on 
a two-dimensional surface and process the signal immediately after photon 
detection. At present, there are three types of area detectors: gas-filled 
ionization type detectors, video-based area detectors and charge coupled 
device (CCD) type detectors. 
The diffraction from a crystal can be described as a summation of the 
enormous number of waves scattered by the electrons in the crystal. 
Because the electrons are bound to atoms, each type of atom is assigned an 
atomic scattering factor /. The atomic scattering factor f is a function of 
(sinelh), where 9 is the diffraction angle and )c is the X-ray wavelength. f is 
equal to the number of electrons in the atom at 0 = 0, and it decreases with 
increasing 9 angle. Next let us consider the case of scattering by a unit cell 
(Figure 2.2). Suppose a unit cell has n atoms at position r, (j = 0, 1. 2. .... n) 
with respect to the origin of the unit cell, and each atom has atomic scattering 
factor as& The total scattering by the unit cell (F(S)) is 
F(S) is the structure factor. It is dependent on the arrangement of the atoms 
in the unit cell. S is the vector perpendicular to the imaginary "reflecting plane" 
and makes equal angles with the incident and reflected beams. 
Figure 2.2. The structure factor F(S) is the summation of the scattering of all 
the atoms in the unit cell. 6s are the scattering vectors of the atoms in the 
Argand diagram with respect to the origin of the unit cell (f, =J; exp[2m,-S]). 
From the diffraction experiment, only I(hk0s are obtained. &hkl)s have 
to be converted to the structure factor amplitudes IF(hkl)(s because it is 
IF(hk1)l s that are used in the Fourier transformation to get the electron density 
map. 
The relationship between I(hkl) and ( ~ ( h k l ) l  is: 
where A is the wavelength, o is the angular velocity that the crystal is rotated, 
V is the volume of the unit cell, V,, is the volume of the crystal, L is the 
Lorentz factor which depends on the data acquisition technique, P is the 
polarization factor, A is the absorption factor, e and nt are the charge and 
mass of an electron, c is the velocity of light, and [o is the intensity of the 
incident beam. 
If we assign K equal to: 
then, 
Because the scale factcr K is normally a constant for any given set of 
measurements, it is commonly omitted for the data reduction calculations. 
Therefore, the structure factor amplitude I ~ ' ( h k l )  1 (also called the observed 
structure factor amplitude I F,, I ) is obtained on a relative scale by calculating 
I(hkO/(L-PA).  The Lorentz and polarization corrections are usually 
incorporated into the software package for processing the intensity data. 
Whether correction for absorption is required or not, depends on the shape of 
the crystal, the wavelength of the X-rays, and the diffraction technique. 
2.3 Phase determination 
The electron density in a crystal can be obtained by the Fourier 
transformation 
in which 1 ~ ( h k n l  is the structure factor amplitude of reflection (hkn, including 
the temperature factor, and or(hk4 is the phase angle. r, y, and : are the 
coordinates in the unit cell. From the previous section, we know that the 
amplitudes I ~ ( h k l ) l  can be obtained from the i(hk0 after applying the 
correction factors of L, P and A. However, the phase angles a h k n  are not 
available. In general, the phases for the reflections can be obtained by one of 
the following methods in protein X-ray crystallography: 
(1 ) Multiple isornorphous replacement method (MI R). This method 
requires the attachment of heavy atoms to the protein molecule in 
the crystal. 
(2) Molecular replacement method (MR). This method is based on the 
similarity of the unknown structure to an already known structure. 
(3) Multiple wavelength anomalous diffraction method (MAD). In this 
method, strong anomalously scattering atoms should be present in 
the protein structure. 
(4) Direct methods. The application of direct methods to protein crystal 
structural determination is still at the preliminary stage. 
Because the structure of RMP was solved by the molecular 
replacement method, only that method will be discussed in this chapter. 
2.4 Molecular replacement (MR) 
Molecular replacement is the most rapid method for solving protein 
structures. In this section, two textbooks, Protein Crystallography (Blundell & 
Johnson. 1 976) and Principles of Protein X-ray Crystallography (Drenth, 
1994), are used as references to give a brief introduction to the molecular 
replacement method. This technique requires that the protein with unknown 
structure and a protein whose structure is known be homologous. The known 
structure of this homologous protein is used as a model for the protein for 
which the structure is to be determined. This method is based on the 
observations that proteins, which have a high homology in amino acid 
sequence, often have homologous three-dimensional structures. 
The molecular replacement method was initiated in pioneering studies 
by Rossmann and Blow (1962). This method transfers the known molecular 
structure of a protein in its native crystal structure to the crystal of the protein 
for which the structure is unknown. This task is carried out in two steps: 
rotation and translation. The rotation is to put the unknown and known 
proteins into the same spatial orientation and the translation is used to 
superimpose the correctly-oriented molecules. The molecular replacement 
method can also be used for noncrystallographic symmetry. 
In both rotation and translation functions, the Patterson functions of the 
protein molecules are used. The Patterson function P(u) is a Fourier 
summation with amplitudes I F(s)(' as coefficients and all phase angles equal 
to zero. 
where V is the volume of the unit cell. 
The Patterson map has peaks at end points of vector u equal to vectors 
between atoms in the unit cell. Therefore, the Patterson map is a vector map 
and is centrosymmetric. If the pair of atoms belong to the same molecule, the 
vector between these two atoms is called a self-patterson vector. If the pair of 
atoms belong to two different molecules, the vector is called a cross-Patterson 
vector. The self-patterson vectors are used in the rotation search and the 
cross-Patterson vectors are used in the translation search in the molecular 
replacement method. 
2.4.1 The rotation function 
The self-patterson peaks of a molecule all lie in a volume around the 
origin with a radius equal to the dimension of the molecule. If non- 
crystallographic symmetry is present in the crystal, the self-patterson vectors 
for each of the molecules in the asymmetric unit will be the same except for a 
rotation that is the same as their noncrystallographic rotational symmetry. 
Therefore, maximum overlap between two self-patterson maps can be 
obtained if the two Patterson functions are superimposed on a correct 
rotation. Similarly, the correct rotation of the self-patterson function of one 
molecule onto the self-patterson function of another molecule in a different 
crystal lattice will result in a maximum overlap between the two Patterson 
maps. 
Let us consider one atom located at position x = xlal + x?az + .qa3 in one 
crystallographic lattice with axes a[,  a2, and a3. Rotation of the lattice around 
its origin leads to a new set of axes: a , , ,  a,?, and a,,. The position of the atom 
in this new system is x, = .r,,lar.l + .r,?ar.z + .r,3ar.3 and the relationship between 
the two sets of coordinates is x, = [C] x, where [C] is the rotation matrix. A 
rotation of the axes has the same effect as a rotation of the molecule in the 
opposite direction. The Patterson map rotates as the molecule rotates. 
Applying the rotation matrix [C] to the Patterson function P(u) gives the rotated 
Patterson function PAu,). An overlap function R of P(u) with the rotated P,(u,), 
of the same crystal lattice (self-rotation function) or a different crystal lattice 
(cross-rotation function) is defined as: 
U is the volume in the Patterson map where all the self-Patterson vectors are 
located. a, P and y are the Eulerian rotation angles (Machin, 1985). The 
rotation function R depends on the rotation angles (related to [C]) and will 
reach a maximum value if the Patterson maps are correctly overlapped. 
Now P(u) and P,h,) are expanded as a Fourier series: 
and 
Because ur = [ C ]  u, 
As h' [Clequals to [C" jh' , therefore we get 
Now the rotation function R(a,/?,fi is: 
The integral is an interference function and its value may be written as: 
(UN) G[-(h + [C1] h' )] 
The integration is over a volume symmetrical about the Patterson origin. 
Therefore, the rotation function is: 
If the protein molecule can be assumed to be approximately spherical, 
the function G can be written as: 
I is equal to (h  + [c-'1 h' ) r. 
The function G is shown in Figure 2.3. It has a maximum value of 1 
and is less than 0.086 outside the range -0.725 < x c 0.725. Therefore, all the 
terms in the rotation function for which 1.rl z 0.725 are neglected. 
Figure 2.3. The function G = [3(sin2m - ZlacosZm)]/( 3m)' plotted as a 
function of x (Rossmann & Blow. 1962). 
Because the rotation function is approximately proportional to id4, all 
strong reflections should be present in the calculation. Very low resolution 
data (> 10 A2) can be excluded in the calculation because they are determined 
mostly by the solvent region and insensitive to rotation. 
2.4.2 The translation function 
From the rotation function, the orientation of the unknown molecule is 
determined. No translation is incorporated. However, for the final result of the 
molecular replacement method, the position of the unknown molecule in the 
unit cell has to be determined. This is done by a translation which overlaps 
one molecule onto the other in real space. One way to do this is by trial and 
error. The known molecule is moved through the asymmetric unit and 
structure factors (F,) are calculated and compared with the obsewed structure 
factors (F,,) by calculating an R-factor or the correlation coefficient as a 
function of the molecular position. 
This correlation coefficient is a better index than the R-factor because it is 
scaling insensitive; the replacement of  IF,,^' by kl~,, l '  + a constant (k  is the 
scale factor for the intensities) gives the same value for the correlation 
coefficient. 
In a more straightforward method than the trial and error search, a 
translation function is investigated. In this method, the correlation between a 
set of cross-Patterson vectors for a model structure and the observed 
Patterson function is calculated. The cross-Patterson vectors are the 
intennolecular vectors. 
Let us assume that crystals of the unknown structure belong to a space 
group which has at least two equivalent positions. Consider a pair of 
molecules which are symmetry-related (Figwe 2.4). Their orientations are 
known from the rotation function, but not their positions in the unit cell. From 
the translation function, the position of molecule 1 with respect to symrnetiy- 
related molecule 2 can be determined, and subsequently the relative position 
of any other pair of symmetry-related molecules can be determined. In space 
group PI ,  no crystallographic symmetry exists. The origin can be chosen 
anywhere and this has no influence on the absolute value of the structure 
factor. Therefore, the calculation of the translation function is not necessary 
for triclinic protein crystals. 
Figure 2.4. The position (x) in molecule 1 and (x + u) in molecule 2. 0, and 
O2 are the local origins. 
The origin of the unit cell is at 0. The local origins of molecules 1 and 2 
are 0, and 02, respectively. The cross-Patterson function between these two 
molecules is: 
If the electron density expressed with respect to the local origin of the first 
molecule, the model molecule M, is PSI, then 
and 
for the local origin in 0 2 .  This is equal to the electron density in the model 
molecule (molecule 1) at the symmetry-related position [c-I] (x + u - [CIS - d 1. 
[C] is the matrix that transfers molecule 1 to molecule 2, and LC-'] is the 
inverse matrix of [C]. Therefore, 
Now the cross-Patterson function is: 
If the intermolecular vector t is between 0, and 02, 
t = -s+[C]s+d 
Now we write phf as a Fourier series in terms of the structure factor F, and 
then simplify the cross-Patterson function. The simplified cross-Patterson 
function is: 
P ; , ,  (u. t) = F,, (h) . F,;, (h[C]) exp[-2dh. t ]exp[-2~h - u] 
h 
This is the cross-Patterson function of the model structure in which two 
molecules are related by crystallographic symmetry. F;, is the complex 
conjugate of FdV. 
The translation function T(t) is calculated as: 
The translation function T(t)  will reach a maximum if the intermolecular vector 
t is equal to the true intermolecular vector to. If we put the Fourier expansion 
form of PIv2(u.t) into the translation function and replace P(u) with 
x, IF, @)I2 exp[-?nip - u]du , we get the translation function as: 
The integral vanishes unless h-p=O or h=p. Therefore, the translation function 
is re-written as: 
This Fourier summation is the final form of the translation function. Because 
all the coefficients in the summation are known, the translation function can be 
easily calculated. 
2.5 Refinement of the model 
When an approximate initial model is obtained by MIR, MAD or MR, the 
model is subjected to refinement. A crystallographic R-factor is usually used 
as an index of closeness between the model and the real structure. The 
R-factor is calculated by the following equation: 
in which, 
amplitudes 
IF,,I and IFJ are the observed and calculated structure factor 
for reflection (hkn ,  respectively. k is a scale factor. 
In the refinement, the model is adjusted so that a closer agreement 
between the calculated and observed structure factors can be reached. 
Although many computer programs are available for structure refinement, they 
all fall into one of the two common refinement methods: least-squares 
refinement and simulated-annealing refinement. All these refinement 
programs use empirical restraints or constraints to ensure that a reasonable 
structure ensues during the refinement steps. In the refinement, the positional 
parameters and the temperature factors for all the atoms except hydrogen 
atoms are adjusted. Usually only the hydrogen atoms linked to polar atoms 
are placed by geometry on the corresponding non-hydrogen atoms and 
assigned fixed temperature factors (e-g. 15 A'). Because Powell energy 
minimization with the conjugate gradient method (Powell, 1977) was used in 
the refinement of the structures of RMP and its pepstatin A complex, a brief 
introduction to this method is given in this section. For a well-refined protein 
structure, the R-factor is usually less than 25%. However, it has been found 
that some incorrectly-built protein structural models can have similar R-factors. 
To detect this situation, Brijnger (1 WZa, 1993) introduced a cross-validation 
scheme based on a new index called R-free. In this method, the unique 
reflections are divided into two groups: a ''test set (T)" and a "working set (W)". 
The test set is a random selection of about 5 - 10% of the observed 
reflections. The refinement is carried out with the working set only, and the 
R-free is calculated with only the test set of reflections by the following 
equation: 
where hkl c T means all the reflections in the test set T. Thus, R-free is 
unbiased by the refinement process. 
2= 5 1 Least-squares refinement 
The least-squares refinement in protein crystallography is based on the 
principle of least-squares. From the data reduction step, the amplitude of 
structure factor l ~ , ( h k l ) l  can be obtained from I(hk0. From the preliminary 
model, values for the structure factors F,(hkl) can be calculated. The least- 
squares refinement is used to bring the values of l c - (hkl ) (  as close as possible 
to 1 F, (ltkl)( for all reflections (hkl) by varying the parameters of the model. The 
parameters that can be varied in the model are the atomic coordinates and 
the atomic or the overall model temperature factors. The function to be 
minimized in the least-squares refinement is the function Q. 
The summation is over all crystallog rap hically-independent reflections and 
w(hkl) is the weight given to an observation. For small molecule 
crystallography, w(hkl) is usually equal to l / d (hk f ) .  For protein 
crystallography, ~ ( h k l )  is a sit~6!/A-dependent function. In the process of 
minimizing the function Q, the atomic parameters U, (j = lJ.3 ... n) that 
determine l<.(hkl)l are varied. The minimization of the function Q is carried 
out by setting the differentials of Q with respect to all u, equal to zero: 
dQ / du ,  = 0 or 
The observed structure factor amplitudes ( I F  (hk1)l) are constants and the 
amplitudes of the calculated structure factors ( I ~ . ( k k l ) ( )  are dependent on the 
variables 11,. To solve these equations, each I ~ . ( h k l ) l  is expressed in a Taylor 
expansion: 
I F  (hkl;  u ) l =  1 F .  (hkl: i t ,  )I + E ,  
u ,  
1 2 1 F(W;  L ~ ) I  
+ -CCE,E, 3 + "' 
- I ac , ad, 
IF,-(hkl;~c)l indicates that the IF,j depends on the parameters M .  The initial 
values of 1t are 11, and are changed by a small amount E. For parameter 
E = - i , .  [dl< (hk2;u)l l adi] is the differential of IFC-(hkl;u)l with respect to u i  
" , 
calculated at the starting value u,. Because the E values are very small, higher 
order terms in E are neglected. Now putting the Taylor expansion form of 
I F -  (hkl)l back into the differentials of Q equations, the so-called normal 
equations are obtained: 
With these n equations (j = l-m), the E values have to be found and applied to 
the variables ri. With the truncation of higher order terms of the Taylor series 
the final results can be approached by iteration. 
These normal equations are usually solved in the abbreviated forms: 
C,(EA, ) -~ ,  = 0 *
For j = 1 :  c z , , ~ ,  +n, ,&,  +a!,&,+---= b, 
j = 2  a,,&, +a,,&, + a z Z ~ 3 + - . . =  b2 
These equations can be expressed in matrix form: 
a,, a,, a,, ---- 
I a, a,, ---- 
or (A] x [E] = [b]. [A] is called normal matn'x and its elements are 
dl F .  (hkl; u)l 
hkl 
'f, 
[E ]  is the unknown vector. [b] is the gradient vector and its elements are: 
dl<- (hkl; ic)( 
~ ( h k l ) ( J ~ ,  (hklll- I<. (hkl; u)l) x 
hkl 
u. 
Above is the principle of the least-squares refinement used in X-ray 
crystallography. 
2.5.2 Simulated Annealing 
In the process of least-squares refinement, the refinement follows a 
downhill path to minimize the function. If the starting model is not very 
different from the real structure, the refinement can converge easily to the 
correct solution. However, if the starting model is quite far away from the real 
structure, the refinement may be trapped in a local minimum instead of a 
global minimum state. To solve this problem, Bmnger et ai. (1 987) introduced 
simulated-annealing refinement, which allows both downhill and uphill 
searching to try to ensure that the refinement can reach the real minimum. In 
this refinement, the dynamic behavior of a system of particles is simulated. 
This simulation yields an ensemble of structures that is energeticaliy allowed 
for a given temperature and pressure. The energy distribution of the 
structures in the ensemble follows Boltzrnann's law, i.e. the potential energy 
Epor is proportional to e x p [ - ~ ~ , l k T ] ,  where k is the Boltzmann constant and T is 
the absolute temperature. The potential energy depends on the relative 
positions of the atoms. In this method, the electrostatic term is also included. 
This term is defined as: 
Q is the permittivity constant; E, is the local dielectric constant, which is given 
an estimated value between 1 and 80; r ,  is the intermolecular distance 
between two atoms at i and J positions; q, and q, are the charges on these two 
atoms, respectively. 
A molecular dynamics calculation on a molecule is initiated by 
assigning the atoms velocities which are derived from a Maxwell distribution at 
an appropriate temperature. At time r=O, the atoms are in a starting 
configuration with a potential energy E, for the entire molecule. On each 
atom i at position r,, a force is acting. This force is derived from the potential 
energy: force (i) = -dE,,, 1 dr, . From the Newton equation it is known that the 
force (i) is equal to mi(d2ri  l d t ' )  where mi is the mass of atom i. Therefore, 
the acceleration dLr, I dt ' for atom i with mass mi can be calculated and then 
applied. After a short time step At, in the femtosecond range (1 fsec. = 10"~ 
sec), the process is repeated with the atoms in the new positions. If the 
number of steps is sufficient (10'-104), the minimum of EP,, is reached and 
information about the dynamic behavior of the atoms in the molecule is 
obtained. If the temperature of the system is raised to a higher value, more 
atoms will have a higher speed and a higher kinetic energy, and therefore can 
overcome higher energy barriers. The basic idea of this refinement method is 
to raise the temperature high enough so that the atoms can overcome higher 
energy barriers and then slowly cool down to approach the energy minimum. 
In the application of this method to crystallographic refinement, the 
calculated structure factors of the system are restrained to the observed 
structure factors as target values, by adding the crystallographic discrspancy 
term 
as a pseudoenergy term to the potential energy EP,, of the system. k, is a 
weighting factor and k is the scale factor between le,(hki)l and 1F~hkl)l  with 
I<- (hk1)l calculated for the present model. 
The total energy, E, + E,,,, is minimized in the simulated-annealing 
refinement. In principle F, must be calculated after each time step AI as are 
the derivatives of 151 with respect to atomic parameters. These derivatives 
are required for calculating the "force". However, the atomic parameters 
change very little during At and therefore, it is sufficient to calculate Fc- and its 
derivatives until a preset change in the coordinates has been reached, e.g.. 
1/10 of the resolution. 
2.5.3 Powell minimization 
Powell minimization is the energy minimization refinement using the 
conjugate gradient method of Powell (1 977). The conjugate gradient method 
is an iterative process that gives the solution for an n-dimensional problem in 
approximately n steps. In the Powell refinement, the minimization is started 
from the atomic coordinates x, y, Z, and the minimized coordinates are 
returned in X, y, z to start another cycle of minimization. The basic idea of the 
conjugate gradient method is as following. 
Let us assign x as the vector of variables and F(x)  as the objective 
function of x. The gradient vector g(x) can be calculated 
g w  = W x )  
The conjugate gradient method does not require any second derivatives. It is 
an iterative process and converges to the point in the spaces of variables at 
which F(x)  is least. If k is assigned as the number of the current iteration 
starting with k = 1, the gradient vector required for the iteration process is 
9, = Em,) 
For k = 1 , let dk be the steepest descent direction 
d ,  = -g, 
t > I , d ,  = -g ,  + &d,-, where p, = llg, 11' ICk-l i l l . 
The vector xr+, is obtained by searching for the least value of F(x)  from xt 
along the direction dk. 
X I + ,  = X, + k k d k  
where I ,  is the value of L that minimizes the function of one variable 
# k ( A ) =  F(xk f Mk). 
This function completes the iteration and another cycle is started if F(xk+l) or 
gk+, is not sufficiently small. 
Chapter 3. Crystal Structure of RMP at 2.15 A 
3.1 Structure solution and refinement 
3.1.1 Purification 
The first and the most important step in protein crystallographic studies 
of proteins is the crystallization of the proteins. The crystallization requires 
pure protein samples. RMP was obtained from the fermentation of 
Rhizomucor miehei. The purification procedures of RMP were published by 
Jia et a/. (1995) in preliminary studies of RMP. The protocols used for 
purification of this enzyme are as follows: 
(1) Ion-exchange chromatography on SP-Sephadex C50 in 0.05 M 
citrate buffer, pH 3.2, with 0.1 M sodium chloride and elution by 0.1 - 
0.3 M sodium chloride gradient. 
(2) Concentration of the fractions with milk-clotting activity by 
ultrafiltration using DDS membrane type 800 (M, cutoff is about 8 to 
1 0 kDa). 
(3) Exchange of buffer on a Sephadex G50 medium eluted with 0.02 M 
piperazine1HCI buffer, pH 5.3. 
(4) Ion-exchange chromatography on DEAE-Sephadex A50 in 0.02 M 
piperazine1HCI buffer, pH 5.3, and elution by a 0-0.6 M sodium 
chloride gradient. 
(5) Concentration by ultrafiltration using a DDS membrane type 800. 
(6) Gel-filtration on Sephadex G75 superfine using 0.1 M acetate 
buffer, pH 6.0, with 0.1 M sodium chloride. 
(7) Concentration by ultrafiltration and continuous washing with distilled 
water, and then freeze drying. 
In this research project, 500 mg RMP sample purified by the above 
protocols was provided by the laboratory of Dr. Palle Schneider, Department 
of Enzyme Research, Novo Nordisk, DK-2880 Bagsvaerd, Denmark. 
3.1.2 Crystallization 
The crystallization conditions of RMP were first published by Jia et a/. 
(1 995). Subsequently better quality crystals were obtained under improved 
conditions by a repeated seeding method (Thaller ef a/., 1981). Needle-like 
seed crystals were grown by the hanging drop vapour diffusion method with 
25 mg/mL protein solution (10 mM sodium citrate buffer, pH 3.6, 6% 
PEG 8000) suspended over 12% PEG 8000 reservoir solution (1 0 mM sodium 
citrate buffer, pH 3.6) at 21 OC. Seed crystals were washed by transferring 
them to 14% PEG 4000 ( I 0  mM sodium citrate buffer, pH 4.0), and put into 5 
mglml protein drops (5 mM sodium citrate buffer, pH 4.0, 10% PEG 4000) to 
equilibrate over 1 30h PEG 4000 reservoir solutions (1 0 mM sodium citrate 
buffer, pH 4.0). ARer two weeks, the seed crystals had grown a little larger. 
These larger crystals were used as seeds for another cycle of seeding under 
the same conditions. Large crystals suitable for data collection were obtained 
after 4 - 5 cycles of seeding. Because repeated seeding will often increase 
the crystal mosaicity, a compromise must be made between the crystal size 
and the crystal mosaicity. The crystals belong to the orthorhombic space 
group P2,2,2,. The cell dimensions were: a = 41.86 A, b = 51 -21 A, c = 
174.24 A, or = P = y = 90". There is one enzyme molecule per asymmetric 
unit. The molecular mass of the protein is 38.7 kDa and the volume per unit 
mass or Matthews coefficient (Matthews, 1968), V, is 2.41 A3/dalton. The 
solvent content is estimated at 49% (Jia et a/., 1995). Detailed crystal data 
are summarized in Table 3.1. 
Table 3.1 . Crystal data of Rhizomucor miehei aspartic proteinase 
Molecular mass 38.7 kDa. 
Number of residues 36 1 
Crystal size 0.50 x 0.35 x 0.02 mm 
Space group 42,2, 
Cell dimensions a=41.86A, b=51.21 A, c= 174.24A 
Cell content One molecule/asymmetric unit, Z = 4 
Solvent content 49% 
3.1.3 Data collection and processing 
The crystals of RMP were mounted in thin-walled glass capillary tubes 
1 mm in diameter. X-ray data were collected to a maximum resolution of 2.1 5 
A at beamline XI1 (EMBL beam line), DORIS ring, DESY synchrotron in 
Hamburg. The wavelength used was 0.927 A. The oscillation angle was 0.7 
degree. The data were collected with a MAR image plate at 20°C and 
processed using the programs DENZO and SCALEPACK (Otwinowski, 1993) 
and the CCP4 suite (Collaborative Computational Project #4, 1994). A total of 
121,713 reflections to 2.1 5 A resolution were merged to yield 19,858 unique 
reflections with a merging R, of 0.058 for symmetry-equivalent reflections 
based on intensities. The data set was 93.8% complete from 15 to 2.1 5 A. 
The R ,  and completeness for each of the resolution shells are summarized in 
Table 3.2. 
3.1.4 Phasing results - Molecular replacement 
The crystal structure of RMP was solved by the molecular replacement 
method. The preliminary molecular replacement solution was obtained by 
Jia et at. (1995) with an incomplete data set of poor quality, using the 
coordinates of Mucor pusillus aspartic proteinase (MPP) as a search model. 
Some flexible regions of the MPP search model were omitted. The molecular 
replacement calculations were repeated with 10 to 4.0 A, 10 to 3.5 A and 10 
to 2.8 A resolution synchrotron data, respectively, using the program AMoRe 
(Navaza, 1994); essentially the same result was obtained. In the rotation 
search, the strongest peak was about 10 o strong and the second strongest 
peak was about 5 o strong. After the translation search the R-factor was 
48.0%. The rotation and translation results are summarized in TabIe 3.3. 
Rigid body refinement using the program X-?LOR (Brunger, 1992b) was first 
applied to the entire molecule and then allowing relative movement of the two 
domains (residues 5-1 86 and 1 87-361) in the resolution range 10 to 2.8 A. 
Table 3.2. F),, and data completeness for each resolution shell (1 > 0) 
Resolution range (A) k* Completeness (%) 
15.00 - 5.73 0.036 97.5 
5.73 - 4.59 0.039 97.7 
4.59 - 4.02 0.045 98.3 
4.02 - 3.66 0.050 98.9 
3.66 - 3.40 0.053 98.0 
3.40 - 3.20 0.060 97. I 
3.20 - 3.05 0.070 97.3 
3.05 - 2.91 0.078 96.3 
2.91 - 2.80 0.09 1 95.2 
2.80 - 2.71 0.1 02 94.2 
2.71 - 2.62 0.1 14 94.7 
2.62 - 2.55 0.1 24 92.4 
2.55 - 2.48 0.1 39 93.4 
2.48 - 2.42 0.1 57 91.6 
2.42 - 2.37 0.1 62 91.5 
2.37 - 2.32 0.1 69 91 .I 
2.32 - 2.27 0.1 82 89.3 
2.27 - 2.23 0.1 97 89.9 
2.23 - 2.1 9 0.21 3 86.2 
2.19 - 2.15 0.261 83.8 
All reflections 0.058 93.8 
Table 3.3. Molecular replacement result 
Rotation (degree) a = 11 5.55 
p = 69.30 
y= 283.97 
Translation (fractions of cell edges) d~ = 0.290 
Ay = 0.498 
dz= 0.413 
3.1.5 Model building and refinement 
Using the two domain rigid body refinement, it was found that the 
position of the C-terminal domain was statistically significantly different from 
the position in the preliminary solution of Jia et al. (1995). The R-factor was 
47.7OA at this stage. The model was then subjected to further refinement 
using the molecular dynamics program X-PLOR (Brijnger, 1992b). The 
refinement was carried out using the reflections with F,, > 20(F, , )  in the 
resolution range 6.0 to 2.1 5 A. The general refinement protocol was used: 
( I )  check step (to obtain weights for the diffraction data); (2) preparation stage 
(to relieve strains or bad contacts of the initial coordinates); (3) slow cooling 
refinement (simulated-annealing refinement); and (4) Individual B-factor 
refinement. Powell minimization was used in the preparation and slow cooling 
stages. In the slow cooling refinement, the temperature was raised to 3000 K 
first, and then slowly cooled to 300 K in steps of 50 K with energy 
minimization in each step. During each cycle of refinement, a SlGMAA 
weighted 2$,-F, map (Read, 1986) was calculated and model adjustment was 
performed with the use of the TURBO-FRODO program (Roussel et al., 1990) 
on a Silicon Graphics Indigo II computer. In total, 40 cycles of model building 
and refinement were performed, yielding a final R-factor of 21 .50h for 18,842 
reflections with Fo greater than 20(F0) in the range from 6.0 to 2.1 5 A. Water 
molecules with electron density > 3.5 o in the SlGMAA weighted F,,-$. map 
were added to the model in the last seven cycles. After the B-factor 
refinement of each cycle, water molecules with B > 70 AZ were rejected. In 
the final model, 140 water molecules were included. The "free-R-factor" (R- 
free) (Brihger, 1992a) was also calculated for every cycle except the last cycle 
of refinement by omitting a set of randomly selected data that comprised 
about 10% of the observed data. The R-free in the second last cycle 
refinement was 28.1%. In the last cycle of refinement, all of the data with 
F,, > 2 d F , , )  were included and final R-factor was 21 5%. The geometry of the 
final model was examined by the geometry analysis protocol (geomanal) in 
the program X-PLOR. The results of the geometry analysis, together with the 
X-PLOR refinement results, are summarized in Table 3.4. The coordinates of 
RMP have been deposited in the Brookhaven Protein Data Bank with ID code 
2ASI. 
Table 3.4. X-PLOR refinement and geometry analysis results 
Number of protein non-hydrogen atoms 
Number of water oxygen atoms 
Number of carbohydrate non-hydrogen atoms 
R.m.s. coordinate error (A) from a Luuati plot 
Number of unique reflections used in refinement 
Resolution range (A) 
Conventional R-factor 
R- free 
R.m.s.d. for bond distances (A) 
R.m.s.d. for bond angles (degree) 
R.m.s.d. for dihedral angles (degree) 
R.m.s.d. for impropers (degree) 
Average 6-factor for the protein (k) 
Average B-factor for N-terminal domain (A2) 
Average B-factor for C-terminal domain (k) 
Average B-factor for water molecules (A2) 
Average 6-factor for carbohydrates (A2) 
Average B-factor for residues 82-88 (k) 
3.2 Results and discussion 
3.2.1 Quality of the model 
The crystal structure of RMP has been refined to a conventional 
crystallographic R-factor of 21 -5% and a R-free of 28.1 % at 2.15 A resolution. 
In the final model, 2644 protein non-hydrogen atoms, 140 water molecules 
and 39 carbohydrate atoms are included. Four N-terminal residues, Gly85 
and the side-chains of eighteen surface residues were omitted in the 
refinement due to insufficient indication of their positions in the final electron 
density map. Out of the eighteen omitted surface residues, three are in the N- 
terminal domain and the other fifteen are in the C-terminal domain. These 
residues are listed in Table 3.5. The final results of the refinement are given 
in Table 3.4. Electron density maps (2F,,-F,) showing the active site and part 
of the Psheet structures are reproduced in Figure 3.1. 
The main chain torsion angles (#, v) of RMP were examined by the 
program PROCHECK (Laskowski et al., 1993). A Rarnachandran plot 
(Ramachandran & Sasisekharan, 1968) is given in Figure 3.2. Except for the 
glycine and proline residues, all of the residues are in the allowed regions. 
Table 3.5. Omitted regions in RMP model 
Alal to Asp4 All atoms 
Lys53 Side-chain atoms 
Thr84 Side-chain atoms 
Gly85 All atoms 
Arg115 Side-chain atoms 
Arg204 Side-chain atoms 
Ser223 Side-chain atoms 
Arg227 Side-chain atoms 
Ser248 Side-chain atoms 
Ser251 Side-chain atoms 
Glu263 Side-chain atoms 
Gln266 Side-chain atoms 
Ser274-TyR75 Side-chain atoms 
Asn277-Lys279 Side-chain atoms 
Glu297 Side-chain atoms 
Asp310 Side-chain atoms 
Asn326 Side-chain atoms 
The average 6-factors for the main chain and side chain atoms of each 
residue in RMP have been calculated. The diagrams of the average B-factors 
of main chain and side chain atoms versus the residue numbers are shown in 
Figure 3.3. From the figure, it can be seen that the 8-factors for the 
C-terminal domain residues are higher than those for the N-terminal domain 
residues. Within the N-terminal domain, residues 82 to 88 show the highest 
B-factors. 
(a). Active site 
Figure 3.1. Stereo electron density maps (2F,,-Fc) at the active site (a) and 
part of the Psheet structures (b). This Figure was prepared by SETOR 
(Evans. 1993). 
(b). Part of the psheet structures. 
Phi (degrees) 
Figure 3.2. Ramachandran plot of RMP. Glycine residues are shown as 
triangles. 
Main Chain 
Residue number 
Side chain 
Residue number 
Figure 3.3. B-factors of main chain and side chain atoms versus residue 
numbers. 
3.2.2 Overall fold 
RMP contains two domains of approximately the same number of 
residues, consisting predominantly of Psheet structures. The N-terminal 
domain includes residues 1 to 186 and the C-terminal domain includes 
residues 187 to 361. A ribbon representation of the enzyme secondary 
structure and overall folding is shown in Figure 3.4. It is obvious that the 
active site and substrate binding site are located in a deep cleft situated 
between the two domains. The two catalytic aspartates are situated in the 
middle of the cleft, with one contributed from each of the domains. Structural 
studies of the inhibitor-enzyme complexes of other aspartic proteinases (Bott 
et al., 1982; Suguna et a/., 1987; Foundling et a/., 1987a,b; Hoover et a/., 
1991; Pitts et a/., 1995) have shown that the inhibitors fit into the cleft upon 
binding to the enzymes. The average B-factor for the C-terminal domain of 
RMP is 48.0 &, which is 18.9 A2 higher than the average B-factor of 29.1 A2 
for the N-terminal domain. This indicates that the C-terminal domain is more 
mobile than the N-terminal domain in the RMP molecule. ~ a l i  et a/. (1989) 
reported that only a sub-domain in the C-terminal domain, which is about 70% 
of the C-terminal domain, is flexible in the endothiapepsin molecule. This 
phenomenon has also been observed in other aspartic proteinases (Sielecki 
et al., 1990; Cooper et al., 1990; Abad-Zapatero ef a/., 1991). 
Figure 3.4. The stereo ribbon representation of the secondary structure and overall folding of RMP. This Figure 
was prepared by SETOR (Evans, 1993). 
In order to examine the presence of such a flexible sub-domain in 
RMP, the average 6-factor for the corresponding residues (residues 21 1 to 
331 ) and the average 8-factor for the remainder of the residues (rigid group 1 : 
residues 187 to 210 and 332 to 361) in the C-terminal domain of RMP were 
calculated. The average B-factor for the sub-domain is 54.8 & and the 
average B-factor for the rigid group 1 is 34.7 k. Thus, RMP also has a 
flexible sub-domain. The average 6-factor for rigid group 1 is still about 19% 
higher than that of the N-terminal domain. Rigid group 1 is between the 
N-terminal domain and the sub-domain in the C-terminal domain (Figure 3.5). 
Some residues of rigid group 1 are involved in the formation of the interface 
between the N and C-terminal domains. 
A view of the a-carbon backbone of the RMP molecule is shown in 
Figure 3.6, and a diagram showing the packing of RMP molecules within the 
unit cell is presented in Figure 3.7. Apparently the major reason for the 
different thermal parameters of the two domains in RMP is crystal packing. A 
space filling model of RMP is shown in Figure 3.8. The N-terminal domain is 
shown in blue, the C-terminal domain is shown in green, and the residues 
which make surface contacts with symmetry-related molecules are shown in 
red. The N-terminal domain has 30 residues involved in surface contacts with 
symmetry-related molecules and the C-terminal has only 17 residues involved 
in surface contacts with symmetry-related molecules. The N-terminal domain 
has many more surface contacts with symmetry-related molecules than does 
the C-terminal domain in the crystals. Therefore, the mobility of the N-terminal 
domain is restricted by the crystal packing as compared to the C-terminal 
domain. 
Figure 3.5. A stereo presentation of the N-terminal domain, flexible C-terminal 
sub-domain and rigid body 1. The N-terminal domain, rigid body 1 and the 
flexible subdomain are shown in green, yellow and blue, respectively. 
Figure 3.6. Stereo representation of the acarbon backbone of RMP. 
Figure 3.7. The packing of RMP molecules inside the unit cell. 
(a). View 1 of Figure 3.8. 
(b). View 2. 
Figure 3.8. Space filling model of RMP (stereo), showing the interactions with 
symmetry-related molecules. The N and C-terminal domains are in blue and 
green, respectively. The residues interacting with symmetry-related 
molecules are labeled in red. The two views are at approximately 180" to 
each other. 
An active site surface Paairpin loop (residues 82 to 88) shows the 
highest temperature factors (average value 66.6 p) in the N-terminal domain 
and weak density in the electron density map (2F,-F,). Gly85 is omitted in the 
model because the electron density for this residue is very weak. These 
obsewations indicate that this P-hairpin loop is very flexible; it forms a flap 
over the substrate binding cleft. Crystallographic structural studies of other 
aspartic proteinases (Bott et at., 1982; James et a/., 1982) have shown that 
this region undergoes a conformational change and becomes more rigid when 
inhibitors bind to the enzymes. This is due to the formation of hydrogen 
bonds between the inhibitors and the distal portion of the flap (Bott et ab, 
1982; James eta/., 1982). 
There are two disulfide bridges in the enzyme, between cysteines 51 
and 57, and between 272 and 316 (Boel et a/., 1986) The first disulfide bridge 
encloses a 3,,-helix HNI , while the second links two @strands. C7 and C11, of 
the Psheet 2C. The designations of the secondary structure of RMP will be 
discussed in section 3.2.3: secondary structure. 
3.2.3 Secondary structure 
The topological representation of the secondary structure of RMP is 
shown in Figure 3.9. The secondary structure was calculated by the program 
PROCHECK (Laskowski et al., 1993) in addition to manual inspection of 
torsion angles and hydrogen bonding patterns. Both of the two domains 
consist predominately of Psheet structure with a few short helical segments. 
(i) P-Sheets 
The most prominent Ppleated sheet is sheet A, which forms one side 
of the molecule. It consists of six antiparallel Pstrands with three strands from 
each domain. Sheets ZN, 3N. 2C and 3C are formed of anti-parallel 
P-strands, with three, four, four and four strands, respectively. Sheets 1 N and 
1C are formed of mixed pstrands, with eight and five strands, respectively. 
Sheets 2N, I N  and 3N and sheets 1C and 3C are packed approximately 
orthogonal in each domain, forming a three and a two-layered sandwich, 
respectively. This packing has been observed in other proteins having the 
predominantly psheet structure (Chothia & Janin, 1 982). The configuration of 
Figure 3.9. Topological representation of the secondary structure of RMP. 
The Pstrands are represented as arrows and the a-helices are represented 
as rectangles. The 3,,-helices are not shown. 
three strands, N3, N8 and N4, in sheet 1 N resembles the Greek letter y, and 
so this part is also called a ystructure. Sheet 2C is at the outer rim of the 
C-terminal domain. The major force for maintaining this packing is the 
hydrophobic interactions between the side-chain atoms. 
(ii) Helices 
There are five a-helices and seven 3,,-helices in RMP. The longer 
helices are all a-helical, whereas the shorter ones are generally 3,,-helices. 
Only the five a-helices are shown in the topological representation of the 
second structure. The seven 3,,-helices are listed in Table 3.6. In contrast to 
the psheets, which are generally conserved, the helices can undergo large 
variation in positions relative to the Psheets in different as partic proteinases. 
3.2.4 Active site 
In Figure 3.1 0, a van der Waals surface electrostatic potential model of 
RMP calculated by the program GRASP (Nicholls et a/., 1991) is shown. A 
large cleft, where the active site and the substrate-binding site are located, is 
clearly visible between the two domains. The substrate-binding site can 
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Table 3.6. The 3,,-helices in RMP 
Name of helices Initial residue Terminal residue 
HN1 Lys53 Gly56 
HN2 Pro65 Ala67 
HN4 Pro1 38 Thrl4f 
HC1 Asnl89 Leu1 91 
HC3 Ser-274 Gln276 
HC4 Asn302 Leu305 
HC6 Ser356 Tyr358 
accommodate up to eight amino acid residues. The active site has a large 
negative electrostatic potential. As shown in the ribbon representation of 
RMP in Figure 3.4, the two catalytic aspartate residues, Asp38 and Asp237, 
are located at the tips of the  structure and sheet IC, respectively. For 
clarity, the residues at the active site are shown in Figure 3.1 1. The two 
catalytic aspartate residues are approximately co-planar. The conserved 
water molecule, Wat421, bridges the two aspartates by forming hydrogen 
bonds with them at the active site. This type of active site is highly conserved 
in all aspartic proteinases. Structural analysis of the aspartic proteinases by 
both X-ray crystallography and computer graphics has shown that the two 
Figure 3.10. Electrostatic potential model of RMP prepared by the program 
GRASP (Nicholls et a/., 1991). Blue and red represent positive and negative 
electrostatic potentials, respectively. 
Figure 3.1 1. The active site of RMP (stereo). 
90 
catalytic aspartates are related by a local Bfold symmetry (Mantafounis & 
Pitts, 1990). The structure of the ground state for the active site shows that 
there is probably one proton shared between the carboxylates to produce a 
net negative charge (Mantafounis 8 Pitts, 1990). There are quite a few polar 
residues within 10 A from the active site. These residues, together with the 
two catalytic aspartates, are involved in a network of hydrogen bonds, which 
makes this region relatively rigid. The sequence Asp-Thr-G ly-(Sernhr) plays 
a key role in this network (Newman et al., 1993). The hydrogen bonds in this 
network are summarized in Table 3.7. 
At the time when the RMP native structure was solved, no RMP- 
inhibitor complex structures had yet been determined. In order to obtain 
detailed knowledge of the mode of substrate binding in the active site, 
molecular modeling was used to dock the inhibitor pepstatin A molecule into 
the active site of RMP. The pepstatin A sequence mimics residues 102 to 108 
(His-Leu-Ser-Phe-Met-Ala-lle) of ecasein. Pepstatin A coordinates were 
obtained from the endothiapepsin-pepstatin A complex structure (Bailey et a/., 
1993). The endothiapepsin-pepstatin A complex molecule was superimposed 
on the RMP molecule by least squares. The pepstatin A coordinates after 
superposition were combined with the RMP coordinates to give the RMP- 
pepstatin A complex. The RMP-pepstatin A complex structure was then 
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Table 3.7. The network of hydrogen bonds near the active center of RMP 
Table 3.7 continued. 
ThR40 N 
Thr240 0 
Asp237 OD1 
Leu36 0 
Asp38 N 
Wat420 
Trp211 0 
Thr235 0 
The38 OG1 
Asp237 OD1 
Ser41 0 
Ser41 0 
Wat406 
Wat404 
Asp212 OD1 
Wat404 
ThR38 N 
Asn332 ND2 
Asn332 ND2 
Glu18 OEl 
Wat453 
Wat404 
refined by energy-minimization with the program X-PLOR (Bninger, 1992b). 
In the energy-minimization process, the temperature was raised to 2000K and 
then slowly cooled down to 300K. Movement was allowed for both the RMP 
and pepstatin A molecules. The final structure of the complex (Figure 3.12) 
shows that the inhibitor pepstatin A fits into the substrate binding cleft in the 
extended conformation. The possible residues involved in the substrate 
binding are summarized in Table 3.8. The hydroxyl group at the C3 position 
of the P I  -PI' statine residue foms hydrogen bonds with both catalytic 
aspartate residues. This conformation is believed to mimic the transition state 
of the aspartic proteinase-substrate interaction. This structural analysis of the 
native RMP structure and the RMP-pepstatin A complex model from molecular 
modeling fully supports the catalytic mechanism proposed for the aspartic 
proteinases (Pearl, 1987; Suguna et al., 1987; Hoover et al., 1991). The 
proposed catalytic mechanism is shown in Figure 3.13. About one and a half 
years after the RMP native structure was solved, the RMP-pepstatin A 
complex structure was solved at 2.7 A. This structure supports the modeling 
studies and the proposed catalytic mechanism. In Chapter 4 of this thesis, the 
RMP-pepstatin A complex structure and its comparison with the structure 
obtained by molecular modeling will be discussed. 
Figure 3.12. The RMP-pepstatin A complex model from molecular modeling (stereo view). The pepstatin A 
molecules is shown in red. The possible substrate binding residues of RMP are shown in blue. 
Table 3.8. Substrate binding site residues in RMP. 
Substrate Component Subsite residues 
P4 IVA Asn241, Phe242, lle244, Leu321 
P3 Val Thr240, Asn241, Glu19, Leu17 
P2 Val Thr240, lle244, GIy325, l le329, Gly83, Th r84 
PI-PI' STA Asp38, Asp237, Tyr82, Gly83, Gly329, 
Thr240, Gly40, Leu36, Leu132, Pro1 17 
P2' Ala Tyr82, Ser41, Gly40, Phe2lO 
P3'- P4' STA Tyr82, Thr81, lle80, Phe210, Asnl40 
PI' 
Ill l 
Figure 3.13. The catalytic mechanism of aspartic proteinases (Suguna et a/., 
1 987). 
3.2.5 Electrostatic potential and the optimum pH 
All of the aspartic proteinases except renin show maximum activity at 
acidic pH (i.e. pH < 5.0). Renin is usually optimally active at neutral pH (i.e. 
6.5 c pH c 7.0). To carry out the functions at low pH, the enzymes must be 
stable in the acidic environment. Andreeva & James (1991) reported that 
pepsin has a high ratio of potentially negatively-charged groups to positively- 
charged groups, and this high ratio gives the enzyme an unusually stable 
native structure at low pH values. Pepsin has several acidic residues inside 
the protein with depressed pK, values. These residues cause pepsin to 
remain slightly negatively charged even at very low pH values. For most 
proteins the ratio of negatively-charged groups to positively-charged groups at 
neutral pH is close to 1 .O. Thus, as the net charge on the protein increases at 
extreme pH values, the charge repulsion increases and destabilizes the 
protein folding. 
To compare different aspartic proteinases, porcine pepsin numbering 
(Sielecki et ab, 1 990) will be used. The two catalytic aspartic acid residues in 
this numbering system are Asp32 and Asp21 5. The activity at acidic pH for 
aspartic proteinases has attracted the attention of scientists for many years, 
but the reasons for it are still not clear. Studies from two research groups 
(Yamauchi et a/., 1988; Mantafounis & Pitts, 1990) have focused attention on 
a single residue, residue 303. Most aspartic proteinases (e.g. pepsin, 
chymosin b) have aspartate at residue 303. Exceptions are renin (alanine), 
MPP (asparagine) and RMP (asparagine). A similar hypothesis has been 
proposed from these two groups and is shown in Figure 3.14. They propose 
that changes in residue 303 contribute to the differences in the pH optimum of 
catalysis through a mechanism that involves the degree of protonation of the 
active site aspartate residues being affected by polarization of peptide bond 
ThR16-Gly217 by Asp303 (protonated) through a hydrogen bond (OD,- 
H 0 6 )  The polarization effect of this peptide bond is transferred to the 
carboxyl group of Asp21 5 via another hydrogen bond between the main-chain 
N atom of residue Gly217 and one carboxyl oxygen atom of Asp21 5 to affect 
the degree of protonation of Asp215; no such hydrogen bond network can 
form if residue 303 is alanine. Newman et a/. (1993) proposed that for MPP 
the presence of asparagine at residue 303 in place of the usual aspartate 
results in a more basic pH optimum because of the reduced ability of 
asparagine to polarize peptide bond ThR16-Gly217 through a hydrogen bond 
(ND-H..  0 )  In RMP, the corresponding residue at this position (residue 
332) is also asparagine and the pH optimum is 4.7 (Martin et a/., 1980), 
compared to 4.7 for MPP. 
Figure 3.14. The hypothesis proposed to explain why aspartic proteinases 
are optimally active at acid pH (Yamauchi et al., 1988; Mantafounis & Pitts, 
1 990). 
The hypothesis of Newman et a/. (1993) regarding the significance of 
residue 303 MPP was examined and it was concluded that this hypothesis is 
unlikely to be valid. The energy for a hydrogen bond with an uncharged group 
in proteins is only about 0.5-1.5 kcalfmol (Fersht et a/., 1985). Since the bond 
energy difference between the hydrogen bond of 0-H ... 0 (chymosin B) and 
N-H ... 0 (MPP) is likely veiy small (less than 0.5 kcal/mol), the difference in 
polarization of the peptide bond ThR16-Gly217 caused by switching one of 
the oxygen atoms in the hydrogen bond to a nitrogen atom would have little 
significance. It is un likely that this small polarization difference would 
significantly change the ionization state of Asp215 between chymosin B and 
MPP. 
To determine why most aspartic proteinases are most active at acidic 
pH values, the structures of three enzymes, chymosin B (optimum pH 3.7), 
RMP (optimum pH 4.7) and renin (optimum pH 7.0), which possess 
significantly different pH  optima for activity, were examined. The ratios of 
potentially negatively-charged groups to positively-charged groups are 1.6, 
1.9 and 1.2 for chymosin B, RMP and renin, respectively. The calculation of 
this ratio, proposed by Andreeva and James (1991), includes the potentially 
charged residues both on the surface of a protein and inside the protein. 
However, several acidic residues are buried beneath the protein surface in the 
three enzymes. The pH effects on these buried residues are not as significant 
as on the surface residues because the internal acid residues are not likely to 
be ionized. Therefore, one would expect that the high ratio of potentially 
negatively-charged groups to positively-charged groups on the surface of the 
proteins may be more important in stabilizing the proteins at low pH. The 
ratios of the surface charged groups are 1.5, 1.6 and 1.0, respectively, for 
chymosin 8. RMP and renin. These indicate that chymosin 6 and RMP are 
stable at low pH values while renin is stable only at pH near 7.0. 
There are three acidic residues, six polar residues and no basic 
residues within 10 A of the active site in chymosin B; three acidic residues, 
nine polar residues and one basic residue are within 10 A of the active site in 
RMP; there are twelve polar residues and no acidic or basic residues are 
within 10 A of the active site in renin. The active site of each aspartic 
proteinase has a hydrogen bonding network and all of these acidic, basic and 
polar residues, together with the two catalytic aspartate residues, are involved 
in the network. Therefore, the influence of these acidic or basic residues on 
the two catalytic aspartate residues is significantly affected by other residues 
in the hydrogen bonding network. To correlate the effect of all the residues 
close to the active site on the catalytic aspartate residues, the surface 
electrostatic potentials of chymosin B, RMP and renin were calculated by the 
program Delphi (Sharp & Nicholls. 1989). The results of the calculations 
(Table 3.9) show chymosin 6 and renin have the most and least negative 
electrostatic potentials at the active sites, respectively. Because the negative 
electrostatic potentials will decrease the pK, values of the two aspartate 
residues and the optimum pH of each aspartic proteinase is approximately the 
average of the pK, values of the two aspartate residues, it is proposed that the 
Table 3.9. Electrostatic potentials at the active site of 
chymosin B, RMP and renin 
Enzyme Residue Atom type Electrostatic potential (kT) 
chymosin B Asp32 OD1 -650.1 
OD2 -582.5 
Average -61 6.3 
Asp21 5 OD1 -679.1 
OD2 -622.3 
Average -650.7 
D303A chymosin B Asp32 OD1 -642.2 
OD2 -578.9 
Average -61 0.6 
Asp21 5 OD1 -666.2 
OD2 -61 6.3 
Average -641.3 
Asp38 OD 1 -683.9 
OD2 -592.8 
Average -638.4 
Asp237 OD1 -589.0 
OD2 -422.5 
Average -505.8 
lo3 
RMP 
Table 3.9 continued. 
renin 
A31 7D renin 
E19A RMP Asp38 
Asp237 
Asp38 
Asp226 
Asp38 
Asp226 
OD1 
OD2 
Average 
OD1 
OD2 
Average 
OD1 
OD2 
Average 
OD1 
OD2 
Average 
OD1 
OD2 
Average 
OD1 
OD2 
Averaae -594.0 
optimum pH of each aspartic proteinase is determined by the electrostatic 
potential at the active site. This, in turn, is determined by the positions and 
orientations of all the residues near the active site. 
Site-directed mutagenesis studies have shown that the Ala303 to Asp 
mutation in renin results in a downward shift in the pH optimum of 0.5 
(Yamauchi et a/, 1988) and the change of Asp303 to Ala in chymosin 6 results 
in an upward shift of 0.6 unit (Mantafounis & Pitts, 1990). Thus, residue 303 
plays an important role in determining the pH optimum of each aspartic 
proteinase, but other factors must also be important to account for the 
observed differences. Structural comparisons of chymosin B, RMP and renin 
(Figure 3.1 5) show significant conformational differences of residues 303 and 
13. In chymosin B, residue 303 is Asp and is the closest acidic residue to the 
active site (about 6.5 A). Its side-chain points towards the active site, while 
residue 13, which is glutamine, is directed toward the outside of the active site 
and does not interact with Asp303. Asp303 would contribute any negative 
charge to the active site. In RMP, the residues that correspond to porcine 
pepsin positions 303 and 13 are Asn332 and Glu19. The side-chain of Glu19 
points toward the active site and forms a hydrogen bond with Asn332 (unlike 
chyrnosin B, where Gln13 directed away from the active site). In RMP GIul9 
is the closest acidic residue to the active site (about 6.5 A). In renin, the 
(a) chymosin B 
(b) RMP 
(c) renin 
Figure 3.15. Stereo diagrams of the active sites of (a) chymosin B. (b) RMP 
and (c) renin, showing the different conformations of residues 303 and 13 in 
the three enzymes. This Figure is prepared by SETOR (Evans, 1993). 
corresponding residues are Ala317 and Gln19. Gln19 is directed away from 
the active site in renin. 
To isolate the contributions of residue 303 for chymosin B and renin, 
the electrostatic potentials of the hypothetical mutants Asp303Ala (chymosin 
B) and Ala317Asp (renin) were calculated. The contribution of Glu19 in RMP 
was isolated by calculating the electrostatic potential of the mutant Glul9Ala 
(RMP). The results (Table 3.9) show that the Asp303 to Ala mutation in 
chymosin B or the Ala317 to Asp mutation in renin does not cause the 
electrostatic potentials at the active site to increase or decrease to the level in 
RMP. These calculations are consistent with the mutagenesis results quoted 
above. The results also show that changing Glu19 to Ala in RMP does not 
cause the active site electrostatic potential to the level in renin. Therefore, it is 
not expected that the change in the pH optimum for RMP is very large 
although the mutation of Glu19 to Ala might shift the pH optimum upward by 
approximately 0.5 unit in RMP. The above calculations indicate that the 
collective effect of all the residues in the region of the active site is important 
in determining the electrostatic potential of an aspartic proteinase although 
residues 303 and 13 may play a significant role in determining the 
electrostatic potentials at the active site. The results are consistent with the 
present hypothesis in explaining why most aspartic proteinases reach their 
maximum activity at acidic pH. 
3.2.6 Glycosylation and thermal stability 
RMP is the most highly glycosylated among the aspartic proteinases, 
possessing about 6OA carbohydrate (Rickert & McBride-Warren, 1974). 
Previous work (Boel et a/., 1986) had shown that carbohydrate units were 
attached at residues Asn79 and Asn188. By examining the SIGMAA 
weighted 2F0-F, electron density map (Read, 1986), a disaccharide moiety 
NAG-Man and a monosaccharide NAG moiety attached to residues Asn79 
and Asn188, respectively, were located. Brown & Yada (1 991), by comparing 
RMP with its homologues in their kinetic studies, suggested that Asn79 and 
Asn188 were on Ptums on the surface of the molecule. The attachment at 
ptums allows the typically large N-linked structures free rotation, ensuring the 
protective function of the carbohydrate moiety (Montreuil, 1984). However, 
the present results show that neither of the carbohydrate moieties is on a 
b-turn in RMP. Asn79 is in the middle of a Bstrand and Asn188 is on the 
surface loop which connects the two domains. The attachment of 
carbohydrate to a P-strand may limit the positional freedom of the 
carbohydrate due to the steric restraint of the pstrand. The significance of 
this kind of attachment is still not clear. However, because this carbohydrate 
moiety is close to the flexible active site surface flap region (residue 82-88), it 
may mask the flap region from being attacked by other proteolytic enzymes. 
From the structural studies of other aspartic proteinase-inhibitor complexes 
(Bott st a/., 1982; James et a/., 1982; Cooper et a/., 1989; Sali et a/., 1989; 
Bailey et al.. 1993), it is known that this flap is involved in the substrate 
binding. Therefore, the destruction of this flap by proteolysis may reduce 
substrate binding and result in the loss of enzyme activity. Since the surface 
loop where Asn188 is located has greater positional freedom than Pstrands 
or P-turns, the carbohydrate moiety attached to Asn188 is not sterically 
restricted. This lack of steric restraint allows this carbohydrate moiety to block 
access of proteolytic enzymes, thereby conferring protection from proteolysis. 
Recent studies on glycosylated enzymes and glycoproteins have 
shown that N-linked carbohydrates enhance the thermal stability of 
glycoproteins (Doan & Fincher, 1992; Kodama et al., 1993; Chen et a/., 1994; 
Terashima et al., 1994; 0 et a/., 1995). It has been proposed that the N-linked 
carbohydrate chains stabilize the tertiary structure of the glycoproteins 
(0 et al., 1995). One interpretation for this phenomenon is that the 
carbohydrate chains on the glycoproteins have large mobilities. The mobilities 
of the carbohydrate chains increase as the temperature rises. It is likely that 
the vibrational motions of the carbohydrate chains act as heat reservoirs and 
confer higher thermal stability on the glycoproteins. Denaturation studies by 
Brown & Yada (1991) show that the activation energies for the denaturation of 
glycosylated RMP and partially deglycosylated (37.8%) RMP are 458 kJlmol 
and 339 kJIrnol, respectively. These studies are consistent with the 
hypothesis that the carbohydrates act as heat reservoirs in thermally stable 
glycoproteins. The carbohydrates may also prevent the aggregation of the 
transition state (partially-unfolded) forms of the glycoproteins during the 
denaturation process and prolong the presence of the native forms (Brown & 
Yada, 1991). The above rationale may explain why RMP exhibits very high 
thermal stability. 
Deglycosylation studies by Aikawa et a/. (1990) have shown that the 
depletion of the N-linked carbohydrate groups from MPP increases the milk- 
clotting activity and decreases the proteolytic activity and thermal stability of 
the enzyme. Recent studies by Harboe (1996) indicated that RMP 
deglycosylated by endo-P-N-acetylglucosaminidase H had an increase of 30% 
of the clotting activity. Unfortunately, the thermal stability change was not 
reported. However, due to the similarity between RMP and MPP, it is likely 
that deglycosylation of RMP by endo-P-N-acetylglucosaminidase H will also 
result in a decrease in thermal stability. 
The results of mutagenesis studies by Yamashita et a/, (1 994) indicate 
that the substitution of Gly186 by various other amino acids in MPP decreases 
the thermal stability of the enzyme. Glycine does not have torsion angle 
restraints and can be accommodated where other amino acids cannot fit. 
Mutation of Gly186 to any other amino acid would probably increase the strain 
in that region and cause the protein to be less stable, and therefore the 
thermal stability of the enzyme would be decreased. Gly186 in the RMP 
molecule is in a %on-allowed" region of Ramachandran Plot. The possibility 
that the change at position 186 may decrease the mobility of the carbohydrate 
chain at Asn188 cannot be eliminated. It is expected that similar mutants of 
RMP would also show a decrease in thermal stability, due to the high 
structural similarity of RMP and MPP. 
The study of the thermal stabilities of proteins is a very important 
research area and has attracted the attention of many scientists for many 
years. Different explanations have been proposed for the thermal stabilities of 
the proteins, including increased hydrophobic core interaction and increased 
interdomain interface area (Korolev et al., 1995), disulfide bonds (Betz, 1993), 
and internal hydrogen bonding network (Yu et a/., 1995). All aspartic 
proteinases consist predominantly of p-sheet structures, have a hydrophobic 
core and a rigid active site. The network of hydrogen bonds between 
P-strands, the network of hydrogen bonds in the active site, and the 
hydrophobic interactions contributed by the hydrophobic core might be the 
reasons for the high thermal stability of the enzymes. To understand better 
the reason for the thermal stability of RMP, the structures of chymosin 6, 
RMP, MPP and renin were examined. Heat inactivation studies (Hyslop et al., 
1979) show that the temperatures necessary to inactivate the enzymes by 
90% at pH 5.0 in 15 seconds are 82%, 74°C and 72°C for RMP, MPP and 
rennet (chymosin), respectively. The in vitro studies by De Vito et al. (1997) 
showed that renin was rapidly inactivated in rat plasma at 37°C. No 
significant differences in hydrogen bonding and hydrophobic interaction were 
found among these four enzymes in the comparison studies. The main chain 
hydrogen bonds in these four enzymes are shown in Figure 3.16. The 
deglycosylation studies by Aikawa et a/. (1990) on MPP also eliminate the 
possibility that hydrogen bonding networks and hydrophobic interactions 
supply the enzyme with high thermal stability, since the deglycosylation does 
not change the tertiary structure of the enzyme. In a recent minireview by 
Goldrnan (1995), a network of ionic pairs in proteins was suggested to be the 
reason for the high thermal stability of the proteins. However, a thorough 
examination of the RMP structure did not find such a network of ionic pairs in 
RMP. Therefore, it can be concluded that the high thermal stability of RMP is 
primarily conferred by the N-l inked carbohydrates. 
(a) chymosin B 
(b) RMP 
(c) MPP 
(d) renin 
Figure 3.1 6. Main chain hydrogen bonds in (a) chyrnosin B. (b) RMP, (c) MPP 
and (d) renin. These diagrams are in stereo. 
3.2.7 Structure comparison with other aspartic proteinases 
The amino acid sequence alignment of RMP, MPP, chicken pepsin. 
chymosin 6, penicillopepsin, endothiapepsin and yeast proteinase A was 
done by BaudyS et al. (1988). This study shows that RMP has 87% identity 
with MPP and about 22 to 24% identity with other aspartic proteinases. In the 
present study the amino acid sequence alignment of RMP with MPP, 
penicillopepsin, endothiapepsin, chymosin B, human renin and pig cathepsin 
D was carried out. The sequence alignment result is shown in Figure 3.17. 
The result is consistent with the result from Baudy5 et al. (1 988) that RMP and 
MPP are structurally closely-related and are significantly different from other 
aspartic proteinases. After solving the native RMP structure, the final a- 
carbon atomic coordinates were submitted to EMBL, Heidelberg, Germany for 
three-dimensional structural alignments with the DALl program (Holm & 
Sander, 1993). The alignment results are shown in Table 3.1 0. From this 
table it can be seen that RMP has a r.m.s. deviation of 0.6 A from MPP and 
r.rn.s. deviation of more than 1.7 A from the other aspartic proteinases for 21 5 
to 226 equivalent amino acid residues. This indicates that RMP and MPP 
diverged from other aspartic proteinases at an early stage of evolution and 
form a sub-family within the aspartic proteinases. This may explain why 
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AAAM;SVDTPGYYDFDL,EEYAIPVSIGTPGQDFLLLFDTGSSDTWPHKGCTKSE-GCVG 
AEGDGSVDTPGLYDFDLEEYAIPVSIGTPGQDFYLLFDTGSSDTWPHKGCDNSE-GCVG 
--AASGVATNTPTAN-DEEYITPVTIGG--TTLNLNFDTGSADLWFSTELPAS--QQSG 
---STGSATTTPIDSLDDAYITPVQIGTPAQTLNLDFDTGSSDLWFSSETTAS--EVK 
----GEVASVPLTNYLDSQYFGKIYLGTPPQEFTVLFDTGSSDFWPSIYCKSN--ACKN 
LTLGNTTSSVII~TNYMDTQYYGEIGIGTPPQTFKWFDTGSSNVWVPSSKCSRLYTACVY 
- - . - -  -GPIPEVLKNYMDAQYYGEIGIGTPPQCFTWFDTGSSNLWPSIHCKLLDIACWI 
* . . *  * * * * * .  * *  
SRFFDPS-ASSTFKATNYNLNITYGTG-GANGLYF---------- EDSIAIGDITVTKQI 
KRFFDPS-SSSTFKETDYNLNITYGTG-GANGIYF---------- RDSITVGGATVKQQT 
HSVYNP--SATGKELSGYTWSISYGDGSSASGWF---------- TDSVTVGGVTAHGQA 
QTIYTPSKSTTAKLLSGATWSISYGDGSSSSGDW--------- -TDTVSVGGLTVTGQA 
HQRFDPR-KSSTFQNLGKPLSIHYGTG-SMQGILG---------- YDTVTVSNIVDIQQT 
HKLFDAS-DSSSYKHNGTELTLRYSTG-TVSGFLS---------- QDIITVGGITVT-QM 
WHKYNSG-KSSTWKNGTTFAIHYGSG-SLSGYLSSQDTVSVPCNSALSGVGGIKVERQT 
* * 
. . 
* * 
LAWDNVRGPTAEQSPNADIFLDGLFGAAYPDNTAMEAEYGSTYNTVHVNLYKQGLISSP 
LAYVDNVSGPTAEQSPDSELFLDGMFGAAYPDNTAMEAEYGDTYNTVHVNLYKQGLISSP 
VQAAQQI--SAQ---FQQDTNNDC;LLGLAFSSINTVQPQS---QTTFFDTVKSS--LAQP 
VESAKKV--SSS---FTEDSTIDGLLGLAFSTLNTVSPTQ---QKTFFDNAKAS--LDSP 
VGLSTQE--PGD---VFTYAEFDGILGMAYPSLASEYSIP------ VFDNMMNRHLVAQD 
FGEVTEM--PAL---PFMLAEFDGWGMGFIEQAIGRVTP------IFDNIISQGVLKED 
FGEATKQ--PGL---TFIAAKFDGILGMAYPRISVNNVVP------VFDNLMQQKLVDKD 
* * .  * . 
L F S W M N T N - - S G T - - - G E W F G G V N N T L L G G D I A Y T D Y  
VFSVYMNTN--DGG---GQWFGGAfJNTLLGGDIQYTDVLKSRGGYFFWDAPVTGVKIE 
LFAVALKHQ---QP---GWDFGFIDSSKYTGSLTYTGVDNSQG---FWSFWDSYTAGS 
VFTADLGYH---AP---GTYNFGFIDTTAYTGSITYTAVSTKQG---FWEWTSTGYAVGS 
LFSWMDRN--GQE---SMLTLGAIDPSYYTGSLHWPVTVQQ----YWQFTVDSVTISG 
VFSFYYNRDSENsQSI~GGQIVLGGSDPQHYEGNFHYINLIKTG----WQIQMKGVSVGS 
IFSFYLNRD-PGAQ-PGGELMLGGIDSKYYKGSLDYH-QVAVGS 
* * iI * 
. . 
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ISIVMQKSGSSSDTIEISVPVSKMLLPVDQSNETCMFIILPDGGNQYIVGNLFLRFFVNV 
F S L V L Q K S G S S S D T I D V S V P I S K M L L P V D K S G E T C M F I V L  
FSVSISGYTATVPGSLINYGPSGXS-TCLGGIQSNSGIG-----FSIFGDIFLKSQYW 
FTFGVGSARIVIPGDYIDFGPISTGSSSCFGGIQSSAGIG----- INIFGDVALKAAFW 
WFEINGKMYPLTPSAYTSQDQG----FCTSGFQSENHS-----QKWILGDVFIREYYSV 
ISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPP-TGPTWALGATFIRKFYTE 
VTVTLGGKKYKLSSENYTLKVSQAGQTICLSGFMGMDIPPP-GGPLWILGDVFIGRYYTV 
* .  
YD-FGNNRIGFAPLASAYENE 
YD-FGKNHIGFAPLASGYEND 
FD-SDGPQLGFAPQA- - - - - - 
FNGATTPTLGFASK------- 
FD-RANNLVGLAKAI - -- - - - - 
FD-RRNNRIGFALAR- - - - - - 
FD-RDLNRVGLAEAA----- -
* * 
Figure 3.17. Sequence alignment of RMP with MPP, penicillopepsin, endothiapepsin, chymosin b, human renin 
3A and pig cathepsin D. The amino acid sequences were obtained from the SWISS-PROT protein sequence 
data bank. Identical residues among the aligned sequences are highlighted with an asterisk (*), and conserved 
residues with a dot (.). 
molecular replacement search with aspartic proteinases other than MPP did 
not give a solution for RMP and MPP was only able to be solved by multiple 
isomorphous replacement (MIR) method. RMP and MPP maintain the overall 
structural similarity of aspartic proteinases: a large substrate-binding cleft, two 
catalytically essential aspartate residues in the middle of the cleft, mobility of 
the two domains, relative rigidity of the active site due to hydrogen bonding, 
and a highly mobile flap region over the substrate-binding cleft. However, due 
to the differences in the residues in the substrate-binding site, the aspartic 
proteinases may show diverse substrate specifities (Yang et a/., 1997). 
Table 3.1 0. The r.m.s. deviations between RMP and other aspartic 
proteinases from the three-dimensional structural alignments 
Aspartic proteinases source R.m.s. deviation from RMP (A) 
MPP 0.6 
human pepsin 1.7 
rhizopuspepsin 1.8 
chymosin B 1.8 
human renin 1.8 
penicillopepsin 2.0 
endothiapepsin 2.2 
3.3 Conclusion 
The crystal structure of the aspaltic proteinase from Rhimmucor miehei 
(RMP, EC 3.4.23.23) has been refined at 2.15 A resolution to a 
crystallographic R-factor of 21.5% and a R-free of 28.1 %. The root-mean- 
square (r.m.s.) error for the atomic coordinates estimated from a Luuati plot 
is 0.2 A. The r.m.s. deviations for the bond distances and bond angles from 
the constraints in X-PLOR are 0.01 A and 1.7", respectively. RMP contains 
two domains, which consist predominantly of p-sheets. A large substrate 
binding cleft is clearly visible between the two domains, and the two catalytic 
residues Asp38 and Asp237 are located in the middle of the cleft with a water 
molecule bridging the carboxyl groups of Asp38 and Asp237. Due to crystal 
packing, the C-terminal domain is more mobile than the N-terminal domain. 
Most of the aspartic proteinases (except renin) reach their maximum activity at 
acidic pH. From this study it is proposed that the optimum pH of each aspartic 
proteinase is determined by the electrostatic potential at the active site, which, 
in turn, is determined primarily by the positions and orientations of all the 
residues near the active site. RMP is the most glycosylated among the 
aspartic proteinases. The carbohydrate moieties are linked to Asn79 and 
Asn188, respectively. Asn79 is in the middle of a P-strand and Asn188 is on a 
surface loop in contrast to the previous hypothesis proposed by Brown and 
Yada (1991) that they are both on the surface p-turns. RMP has a very high 
thermal stability. The high thermal stability is probably due to the high level of 
glycosylation. It is proposed that the highly flexible carbohydrates act as heat 
reservoirs to stabilize the conformation of RMP and therefore provide the 
enzyme with high thermal stability. Three-dimensional structural and 
sequence alignments of RMP with other aspartic proteinases show that RMP 
is most structurally homologous to MPP, and differs from other fungal 
enzymes as much as it does from the mammalian enzymes. This suggests 
that RMP and MPP diverged from the main stream of aspartic proteinases at 
an early stage of evolution. The present study adds a second member to this 
subfamily of aspartic proteinases. 
Chapter 4. Crystal Structure of RMP-pepstatin A 
complex at 2.7 A 
During the past twenty years, aspartic proteinases have been 
extensively studied due to their diverse biological functions. All members of 
the aspartic proteinase family are closely related structurally. They all contain 
two domains (homodimers for retroviral aspartic proteinases) with the active 
site at the interface of these two domains. In order to determine the catalytic 
mechanism of this group of enzymes, the structures of many aspartic 
proteinases complexed with natural or synthetic inhibitors have been studied 
(James & Sielecki, 1985; Suguna et a/., 1987; Foundling et a/., 1987a,b; 
Cooper et a/., 1989; Abad-Zapatero et al., 1991 ; Hoover et a/., 1991 ; Pitts 
et a/., 1995). These results indicate that a large substrate-binding cleft, which 
can accommodate up to eight amino acid residues, is situated between the 
two domains, and the inhibitors fit into this substrate-binding cleft in extended 
conformations. The residue at P1 (or PI-PI') of the inhibitors interacts with 
the two catalytic aspartates by hydrogen bonds, and this type of interaction is 
believed to resemble the tetrahedral intermediate in proteolytic cleavage of 
the peptide bond (Veerapandian et a/. , 1992). 
The studies of aspartic proteinases complexed with various inhibitors 
have become a very active area with the discovery that HIV proteinases are 
aspartic proteinases. Many competitive inhibitors of HIV proteinases have 
been designed. Three proteinase inhibitors, namely, indinavir, ritonavir and 
saquinavir, with potent anti-HIV activity and favorable pharmacological 
properties have been approved by the United States Food and Drug 
Administration (FDA) for use in humans for the treatment of AIDS. These 
inhibitors can greatly reduce the number of new, infectious copies of HIV 
made inside cells. If these inhibitors succeed in making most new HIV viruses 
defective, the HIV infection would not spread inside the body as quickly as it 
does now. However, due to mutation, HIV viruses show resistance to these 
inhibitors (Otto et al., 1993; Ho et a/., 1994; Kaplan et a/., 1994; Condra et a/., 
1995; Markowitz et a/., 1995). Combinations of HIV proteinase inhibitors and 
combinations of the HIV proteinase inhibitors with the reverse transcriptase 
inhibitors have been studied as potential treatments for AIDS. However, 
these studies are still at the beginning stage and it is too early to say which 
combinations will work best. Combinations of inhibitors may increase known 
side effects or cause new ones (Markowitz, 1996). Very recently, Mr. Bill 
Clinton, the President of the United States of America, called for development 
of an AIDS vaccine (Nature, 1997, Vol. 387, p323). HIV proteinases are still 
the most promising targets and a potent inhibitor, which resists HIV mutations. 
may be a breakthrough in the the search for a cure for AIDS. 
In Chapter 3, it was mentioned that RMP and MPP diverged from other 
aspartic proteinases at an early stage of evolution and form a sub-family of 
the aspartic proteinases. Therefore, the binding of inhibitors to RMP and MPP 
might be different from other aspartic proteinases. As no structures of RMP or 
MPP complexes with inhibitors have been published, the structural study of 
RMP complexed with pepstatin A was carried out. The present study is the 
first structure of an enzyme-inhibitor complex in this subfamily of aspartic 
proteinases and this research will also improve our knowledge of the aspartic 
proteinases. 
4.1 Structure solution and refinement 
4.1.1 Crystallization 
The crystallization of RMP-pepstatin A complex was a tedious process. 
The complex was crystallized by a method which involves the combination of 
repeated soaking and seeding. The inhibitor, pepstatin A, was purchased 
from Calbiochem-Behring C o p ,  USA. Because of the low solubility of 
pepstatin A in water, only 1 :I molar ratio of pepstatin A to RMP was used in 
the crystallization. Crystals of the native enzyme were grown by the hanging 
drop vapour diffusion method with 25 rng/mL RMP solution (20 rnM sodium 
citrate buffer, pH 3.6, 8% w/v PEG 8000) suspended over 26' w/v PEG 8000 
resewoir solution (20 mM sodium citrate buffer, pH 3.6) at 21°C. These thin 
needle-shaped native enzyme crystals were used as the initial seeds for the 
repeated combination of soaking and re-seeding (Thaller et a/., 1981), which 
was carried out by the sandwich drop method. Aliquots of 10 pL precipitation 
solution (20 mM citrate buffer, pH 3.6, 26% w/v PEG 8000) were mixed with 
20 pL aliquots containing protein (25 rng/mL RMP, 0.45 mg/mL pepstatin A, 
20 mM citrate buffer, pH 3.6). The seed crystals then were put into the mixed 
protein drops to equilibrate over the precipitation solution. After about one to 
two months, the crystals, with pepstatin A molecules soaked into the active 
sites of RMP molecules, had grown a little larger. These larger crystals were 
used as seeds for another cycle of soaking and reseeding. The crystals used 
for data collection were obtained after five cycles of this combination of 
soaking and seeding. The size of the crystal used for the synchrotron data 
collection was approximately 0.40 x 0.25 x 0.05 mm. The crystals of the 
RMP-pepstatin A complex grow in the same crystal system as does the native 
enzyme. The space group is P2,2,2,, and the unit cell dimensions are: a = 
41 52 A, b = 50.82 A, c = 172.71 A, a = P = y = 90°. This unit cell is slightly 
smaller than the unit cell of the native enzyme (Yang et al., 1997). There is 
one RMP-pepstatin A complex molecule per asymmetric unit. 
4.1.2 Data collection 
Two crystals of the RMP-pepstatin A complex were mounted in glass 
capillary tubes of 1.0 mm in diameter and were taken to the Brookhaven 
National Laboratory, New York, USA, for synchrotron data collection on 
beamline X12C. The data set was collected with only one crystal. The other 
crystal was damaged during the transportation. The X-ray data of the 
complex were collected with a Brandeis CCD detector to a maximum 
resolution of 2.7 A. The wavelength of the incident radiation was 1 .1 5 A. The 
data were processed using DENZO and SCALEPACK (Otwinowski, 1993). A 
total of 43156 reflections measured to 2.7 A were merged to yield 9360 
unique reflections. The merging R, is 0.092 for symmetry-equivalent 
reflections based on intensities. The completeness of the data set is 84.9% 
up to 2.7 A. The R,, and data completeness for each resolution shell are 
shown in Table 4.1. 
4.1.3 Model building and refinement 
The coordinates of the native RMP enzyme were used as the starting 
model. In the first cycle, the model was refined with all of the reflections within 
the resolution range 8 to 2.7 A, using the X-PLOR package (Brunger, 1992b). 
The following protocols were used in the refinement: (1) check step (to obtain 
the weights for diffraction data); (2) rigid body refinement; (3) preparation 
stage (to relieve strains or bad contacts of the initial coordinates); (4) slow 
cooling refinement (simulated-annealing refinement) and (5) individual B- 
factor refinement. The rigid body refinement was first applied the entire RMP 
molecule and then allowing relative movement of the two domains of the RMP 
molecule. After the rigid body refinement, the R-value was 28.2%. After the 
Table 4.1. R,, and completeness for each resolution shell (I > 0) 
Resolution shell (A) Rsv* Completeness (%) 
50.00 to 5.60 0.235 99.1 
5.60 to 4.45 0.039 100 
4.45 to 3.88 0.043 99.9 
3.88 to 3.53 0.057 99.7 
3.53 to 3.28 0.072 99.9 
3.28 to 3.08 0.094 96.1 
3.08 to 2.93 0.1 20 80.0 
2.93 to 2.80 0.1 54 64.5 
2.80 to 2.70 0.159 47.9 
Overall 0.092 84.9 
B-factor refinement, the R-value dropped to 25.0%. In the slow cooling 
refinement, the system was slowly cooled from 2500 K to 300 K in the steps of 
50 K with energy minimization in each step. SIGMAA weighted 2F0-F, and dF 
(F,,-FJ maps (Read, 1986) were calculated after the refinement. The maps 
were examined using the TURBO-FRODO program (Roussel eta/., 1990) and 
the position of the pepstatin A molecule was located from the dF map. The 
electron density for the pepstatin A molecule was observed at Pocontour level 
in the dF map. The model of the complex was then subjected to six cycles of 
simulated-annealing refinement and sixteen cycles of positional refinement 
with all reflections in the resolution range 8 to 2.7 A. Powell minimization was 
used in the preparation stage, after simulated-annealing refinement in the 
slow cooling stage and in the positional refinement stage. The refinements 
were interspersed with manual model building and adjustments using the 
program TURBO-FRODO. The R-free (test set comprised about 5% of the 
observed data) dropped from 34.2% of the second cycle of refinement to 
28.0% of the second last cycle of refinement. In the final cycle of refinement, 
all reflections were used and the R-value was 19.3% No solvent molecules 
were added to the model. The final results of the refinement are listed in 
Table 4.2. 
Table 4.2. X-PLOR refinement results 
Number of protein non-H atoms 
Number of carbohydrate non-H atoms 
Number of inhibitor non-H atoms 
Resolution range (A) 
Number of unique refs. used in refinement 
Conventional R-value (5%) 
R-free (5%) 
R.rn.s.d. for bond distances [A) 
R.m.s.d. for bond angles (degree) 
R.m.s.d. for dihedral angles (degree) 
R.rn.s.d. for impropers (degree) 
Average B-factor for the enzyme (k) 
Average 8-factor for N-terminal domain (A') 
Average B-factor for C-terminal domain (A') 
Average B-factor for carbohydrate (k) 
Average B-factor for the inhibitor (#) 
Average B-factor for the active site surface flap (A2) 51.7 
Average B-factor for the flexible sub-domain (A2) 45.3 
Average B-factor for the residues in the C-terminal 
domain except those of the flexible sub-domain (A2) 28.6 
4.2 Results and discussion 
4.2.1 Quality of the final model and averall folding 
The structure of RMP complexed with pepstatin A has been refined to a 
crystallographic R-value of 19.3% and a R-free of 28.0% at 2.7 A resolution. 
The error for the atomic coordinates estimated from a Luuati plot (Luuati, 
1952) is 0.3 A. The final results of the refinement are summarized in 
Table 4.2. Three N-terminal residues and the side chains of fifteen residues 
were omitted in the refinement due to insufficient indication of their positions in 
the final electron density map. These residues are listed in Table 4.3. An 
electron density map (2F,,-Fc.) at the inhibitor pepstatin A site is shown in 
Figure 4.1. The final model was also examined for the main chain torsion 
angles (#, W) by the program PROCHECK (Laskowski et a/., 1993). A 
Ramachandran plot (Ramachandran & Sasisekharan, 1968) produced by the 
program PROCHECK is shown in Figure 4.2. Except for the glycine and the 
proline residues, all of the amino acid residues are in the allowed regions. 
A ribbon representation of the RMP molecule cornplexed with 
pepstatin A is given in Figure 4.3. As predicted in Chapter 3, pepstatin A fits 
into the substrate-binding cleft between the two domains of RMP in an 
Table 4.3. Omitted regions in RMP-pepstatin A complex 
Alal to Ala3 
Asp4 
Lys49 
Lys53 
Thr84 
Glu120 
Asn 124 
Arg203 
Set-223 
Set247 
Ser251 
Gln265 
Set274 
Lys279 
Ser29 1 
Val309 
All atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
Side-chain atoms 
extended conformation. The average B-factor for the RMP-pepstatin A 
complex molecule (32.3 A2) is 6.8 A2 lower than that for the native enzyme 
molecule (39.1 A2); this suggests that the complex is slightly more rigid than 
the native molecule. The average B-factor for the flexible C-terminal 
Figure 4.1 . Electron density map (2F,,-FJ at the pepstatin A site. This figure 
is prepared by SETOR (Evans, 1993). 
sub-domain in the complex is about 9.5 A2 lower than in the native enzyme 
structure. This indicates that the flexibility of this su b-domain decreases due 
to the binding of the pepstatin A molecule. However, the average B-factor for 
this flexible sub-domain is still much higher than the average B-factor for the 
N-terminal domain in the RMP-pepstatin A complex structure. This indicates 
that this sub-domain is still flexible compared to the N-terminal domain. The 
reason for the flexibility of this sub-domain is probably that the complex was 
c) -135 -90 -45 0 4'5 9'0 135 180 
a Phi (degrees) 
Figure 4.2. A Rarnachandran plot of RMP-pepstatin A complex, showing the 
main chain torsion angles (@, yl). The glycines are shown as triangles. 
Figure 4.3. A stereo ribbon representation of the RMP-pepstatin A complex. 
crystallized by soaking native crystals with pepstatin A. The crystal structure 
of the complex is the same as the native enzyme and there is no change in 
the interactions between one RMP molecule and its symmetry-related 
molecules, which were presumed to be responsible for differences in mobility 
of the N and C-terminal domains in RMP. 
4.2.2 Comparison with the native enzyme 
In order to examine any conformational change of RMP due to the 
binding of pepstatin A, the coordinates of the RMP-pepstatin A complex 
structure were superimposed with the coordinates of the native enzyme 
(Figure 4.4). The two domains of RMP did not show any movement in the 
complex structure with respect to the native enzyme. No movement of the 
sub-domain was observed either. As only the initial and final stages of the 
inhibitor binding were observed, it is not known whether there were any 
domain movements during the binding process. The average B-factor for the 
flexible sub-domain decreased from 54.8 A' in the native enzyme to 45.3 # in 
the complex. This indicates that the sub-domain becomes less flexible due to 
the binding of pepstatin A. The binding of a pepstatin A molecule does not 
cause any large distortion of the active site of RMP. Only the active-site 

surface flap (residues 82 to 88) and a surface loop (residues 323 to 328) 
underwent conformational changes. The conformational change of the active- 
site surface flap is shown in Figure 4.5. The flap moved towards the inhibitor 
and formed two hydrogen bonds with the inhibitor. The flap covers up 
positions P2-PI '. Its residues are involved in the formation of subsites S2, S1 
and S2'. The average B-factor of the flap (51.7 k) in the complex structure is 
much lower than in the native structure (66.6 k), and this suggests the flap 
becomes more rigid in the complex. The conformational change of the 
surface loop is shown in Figure 4.6. This surface loop is opposite to the 
surface flap at the active site. It shifts about 1 to 1.5 A towards the N-terminus 
of the pepstatin A molecule. Gly325 makes good van der Waals contacts with 
the P2 valine residue of pepstatin A. The average 6-factors for this surface 
loop in the native and complex structures (68.1 AZ and 64.8 A2, respectively) 
are very similar, which indicates that the loop is still flexible in the structure of 
the complex. The flexibility of this loop allows the access of different 
substrates to the substrate-binding site and the release of proteolytic products 
from the enzyme. 
corn 
Figure 4.5. The confonational change of the active-site surface flap. Open 
spheres represent the native conformation. The electron density 
corresponding to Gly85 in the native enzyme structure was not observed in 
the native map, but it is present in the map of the complex. 
STA STA 
Figure 4.6. The confonational change of the surface loop (residues 323- 
328). Open spheres represent the native conformation. 
4.2.3 Comparison with the results from molecular modeling. 
With the development of computer science and increased knowledge of 
the three-dimensional structures of proteins, molecular modeling has become 
a very useful tool in structure-function relationship studies. However, the 
molecular modeling predictions should be tested by X-ray structural studies. 
In Chapter 3, the pepstatin A molecule was docked into the RMP molecule by 
molecular modeling. Although the model was subjected to energy 
minimization, it is not known if the inhibitor pepstatin A conformation was 
correct. Solution of the RMP-complex structure makes it possible to evaluate 
the molecular modeling results. In Figure 4.7, the superposition of the 
molecular structure of the RMP-pepstatin A complex with the molecular model 
is shown. Molecular modeling did not completely give the correct 
conformation of pepstatin A. The pepstatin A molecule in the model is closer 
to the correct conformation at the P4 to PI' region than the P2' to P4' region. 
The central region (P2-PI') in the pepstatin A molecule is the closest to the 
correct conformation. This suggests that energy minimization did not reach 
the global minimum, but was trapped at a local energy minimum state. Also, 
the active-site surface flap did not move closer to the inhibitor during the 
docking and energy minimization. Therefore, although molecular modeling 
Figure 4.7. The molecular structure of the RMP-pepstatin A complex is superimposed with the molecular 
modeling model of the complex. The RMP molecule in the model and complex structure are shown in yellow 
and blue, respectively. The pepstatin A molecule in the model and the complex structure are shown in white 
and red, respectively. 
can provide some useful information it is apparent that X-ray crystal lographic 
studies should be carried out whenever possible. 
4.2.4 Hydrogen bonds 
The inhibitor pepstatin A makes 10 hydrogen bonds with the enzyme. 
A schematic diagram of these hydrogen bonds is shown in Figure 4.8. The 
hydroxyl group at the C3 position of statine PI-PI '  replaces the conserved 
water molecule at the enzyme active site and forms hydrogen bonds with both 
of the catalytic aspartate residues Asp38 and Asp237 (Figure 4.9). This 
conformation mimics the expected transition state of the enzyme-substrate 
reaction. These observations fully support the catalytic mechanism of aspartic 
proteinases (Hoover et a/., 1991 ; Pearl et a/., 1987; Suguna et a/., 1987; 
Veerapandian et a/., 1992) which was discussed in Chapter 3. C3 of the 
statine residue is in the S-configuration. This type of configuration has also 
been observed in other aspartic proteinase-statine type inhibitor complexes 
(Cooper et ab, 1989; ~ a l i  et a/., 1989; Bailey et a/., 1993). Rich et a/. (1 980) 
suggested that the 3s enantiomers of the statine residue at PI-PI '  position 
are much more potent than the 3R enantiomers for pepstatin-type inhibitors. 

The active-site flap moves towards the pepstatin A molecule and forms 
two strong hydrogen bonds with the inhibitor, Gly83 with the PI' CO group 
and Gly84 with P2 CO group. The formation of these two hydrogen bonds 
increases the rigidity of this flexible surface flap. The side chain of Thr240 
rotates about 90" along the C,-Cp bond axis to form two hydrogen bonds with 
the P I  NH and P3 CO groups, respectively. Asn241 forms a hydrogen bond 
with the P3 NH group, using its Os atom, and Gly40 forms a hydrogen bond 
with the P2' NH group. 
P I-P 1'  ST^ 
Figure 4.9. The hydrogen bonds formed between pepstatin A and the two 
catalytically essential aspartate residues. 
4.2.5 The pturn in pepstatin A 
When the CO group of a residue, i, forms a hydrogen bond with the NH 
group of another residue, i + 2, a ).turn is formed. There are two types of 
y-turns, classic and inverse (Milner-White et a/., 1988). The ptum present in 
pepstatin A is shown in Figure 4.10. The CO group of statine residue at 
PI-PI' forms a hydrogen bond with the NH group of the statine residues at 
P3'-P4'. The hydrogen atom in the NH group was placed from geometry of 
the N atom with the N-H bond distance at 0.97 A. The O...H and O...N 
distances are 2.20 A and 2.86 A, respectively. The LO. ..H-N angle is 124". 
This is an inverse ytum. The reason for the formation of this y-turn in 
pepstatin A is that the leucyl side of the P3'-P4' statine residue binds back into 
the S1' subsite because the statine residue at PI-PI '  does not have a side 
chain to occupy subsite SI'. Due to the formation of the y-turn, the extended 
conformation of pepstatin A is disrupted at the P3' position. The formation of 
a y-turn in the pepstatin A molecule is also observed in other aspartic 
proteinase-pepstatin A complexes (Suguna et a/. , 1 992; Bailey et a/. , 1 993). 
Figure 4.1 0. The ptum in RMP. 
4.2.6 Binding subsites 
Pepstatin A fits into the substrate-binding cleft between the two 
domains of RMP mainly in an extended conformation upon binding to the 
enzyme. All of the substrate-binding cleft residues of the inhibitor complex are 
shown in Figure 4.1 1. The subsites' residues, which make van der Waals 
contacts with the inhibitor (d 5 4.0 A), are listed in Table 4.4. As mentioned in 
the previous section, the leucine-like side chain of the statine residue at 
Figure 4.1 1. A diagram showing the substrate-binding cleft residues. 
Pepstatin A is shown in white. This diagram is generated by SETOR (Evans, 
1 993). 
P3'-P4', which should interact with subsite S3', binds back into subsite S1' 
and forms an inverse y-turn in the inhibitor. Due to the movement of the leucyl 
side chain, the carboxyl group of this statine residue is also away from the 
subsite S4' and is pointing towards the solvent. In the complex, the active-site 
flap (residues 82-88) undergoes a significant conformational change. It 
moves close to the inhibitor pepstatin A and covers up positions P2-PI'. Its 
residues are involved in the formation of subsites S2, S 1 and S2'. This flap 
becomes rigid due to the formation of hydrogen bonds and the van der Waals 
interactions with the inhibitor. Residue Tyr82 is involved in the formation of 
subsites S2' and S1, and separates these two subsites. At the S4 subsite, 
Leu321 moves about 0.5-0.7 A toward the side chain of IVA to make good 
van der Waals contacts. Residue lle244 is about 5 A from IVA and forms part 
of the subsite S4. This suggests that modifications to a large group at the P4 
position of the inhibitor may result in better contacts with the subsite and may 
confer stronger inhibition. The IVA side chain also interacts with the P2 valine 
residue by van der Waals contacts (d = 3.8 A). At the subsite S3, the subsite 
residues make good interactions with the side chain of the valine residue at 
the P3 position of the inhibitor. Residue Leul7, which may be involved in the 
formation of the S3 subsite, is about 4-5 A from the side chain of the valine 
residue, and therefore, there is room for a larger side chain. From the above 
analysis, it can be seen that pepstatin A has more hydrogen bonding and van 
der Waals interactions with the enzyme at the central region than at either 
end. Therefore, the inhibitor is tightly bound in the central region and loosely 
bound at both ends. 
Table 4.4. van der Waals contacts between the enzyme and 
pepstatin A (d 5 4.0 A) 
Pepstatin A IVA Val Val STA Ala STA 
Position P4 P3 P2 P I  -PI ' P2' P3'-P4' 
Residues of Leu321 Pro117 Gly325 Pro117 Gly40 Phe2lO 
the enzyme ?he242 Glu19 ThR40 Leu132 Phe210 ThR35 
which make Asn241 Asn241 lle329 Tyr82 Asn140 lle329 
van der Waals Thr240 Gly83 Asp38 Tyr82 Asp237 
contacts with Gly84 Asp237 
pepstatin A Leu36 
Gly40 
G lyZ39 
4.2. 7 Comparison of the pepstatin A conformations in different aspartic 
proteinases. 
Pepstatin A is a universal inhibitor for all aspartic proteinases. 
Therefore, it is important to know whether pepstatin A is in the same 
conformation in all aspartic proteinase-pepstatin A complexes. The Protein 
Data Bank at the Brookhaven National Laboratory, USA, was searched and 
four aspartic proteinase-pepstatin A complex structures were found: 
endothiapepsin (Bailey et al., 1993), rhizopuspepsin (Suguna et a/., 1992), 
human pepsin 3A (Fujinaga et a/., 1995) and human cathepsin D (Baldwin 
et al., 1993). The pepstatin A molecules in these four complexes were taken 
out and superimposed with the pepstatin A molecule in the RMP complex. 
The superimposition is shown in Figure 4.12. The pepstatin A conformation is 
more conserved in the central region (P3 to P2') than at both ends. Selected 
dihedral angles at the central region are listed in Table 4.5. The leucyl-like 
side chain of the statine residue at the P3'-P4' position binds into subsite S1' 
in all five complexes. However, the y-turn is formed only in the 
endothiapepsin, RMP and rhizopuspepsin complexes. The 0.. .N distances 
and LO.. .H-N angles in these five pepstatin A structures are summarized in 
Table 4.6. Because of the reverse of the main chain at the P3' position for all 
Figure 4.12. The superposition of the pepstatin A molecules from the RMP 
(green), endothiapepsin (white), rhizopuspepsin (yellow), human cathepsin D 
(pink) and human pepsin 3A (blue) molecules complexed with pepstatin A. 
five complexes, the carboxyl group at the P4' position of the P3'-P4' statine 
residue is away from the subsite S4' and is in a different conformation for 
each complex. The PI-P2' part of the main chain in the pepstatin A molecule 
in the RMP-pepstatin A complex is about 0.5 to 1.0 A away from the mean of 
this part of the other four conformations. The hydroxyl group at the C3 
position of the PI-PI '  statine residue in the RMP complex is in a different 
Table 4.5. Selected dihedral angles in the central region of the pepstatin A molecule in the different 
pepstatin A-aspartic ptoteinase complexes. 
RMP 126.4" -1 78,6O -1 34,g0 62.7" 76.8O 91.1" 
Endothiapepsin 99.8" -1 75.2" -1 23.4" 59.5" 85.4'' 84.7" 
Rhizopuspepsin 97.4" -1 79.2" -1 11.7O 70.3" 63.8" 91.5" 
human pepsin 3A 98.9" -1 73.5" - 1 20.4" 63.7" 75.6O 82.0' 
Cathepsin D 11 5.9" -1 73.6" -1 26.5" 63.7" 78.6" 79.7" 
The numbering used is IVA(l)-Val(2)-Val(3)-STA(4)-Ala(5)-STA(6). The acarbon atoms in the residues of the 
pepstatin A molecule are labeled as CA and the naming scheme used for the two dipeptide analogue statine 
residues is: 
Table 4.6. The 0.. .N distance and LO.. .H-N angle (P3'-PI ') in different 
pepstatin A molecules in the different complex structures. 
- - 
0.. . N distance (A) LO.. .H-N angle 
RMP 2.86 124" 
endoth iapepsin 3.05 137" 
rhizopuspepsin 3.1 7 135" 
human pepsin 3A 3.84 76" 
human cathepsin D 3.08 86O 
conformation from the other hydroxyl group conformations, which are 
approximately the same in the other four pepstatin A molecules. The 
C,-C,-C,-0 plane of the statine residue at the P I  -PI ' position, which contains 
the hydroxyl group, is at about 50" from the mean plane of the other four 
conformations. In summary, the P3-P2' region of the pepstatin A molecule is 
more conserved in the inhibitor binding than both ends. Because of the 
differences of the residues at the substrate-binding site of the aspartic 
proteinases, the conformation of the P3-P2' region of the pepstatin A molecule 
undergoes minor conformational changes to provide better binding. 
4.3 Conclusion 
The crystal structure of the Rhizomucor miehei aspartic proteinase 
(RMP) complexed with the inhibitor pepstatin A has been refined to a 
crystallographic R-value of 1 9.3% and a R-free value of 28.0% at 2.7 A. In the 
final model, a pepstatin A molecule fits into the large substrate-binding cleft 
between the two domains of RMP in an extended conformation up to the 
alanine residue at P2' position. The dipeptide analogue statine residue at the 
P3'-P4' position foms an inverse y-tum (P3'-PI'), with its leucyl side chain 
binding into the S1' subsite. The inhibitor interacts with the residues of the 
substrate binding pocket by either hydrogen bonds or hydrophobic 
interactions, or both. The hydroxyl group of the statine residue at the PI-PI '  
position foms hydrogen bonds with both the catalytic aspartate residues 
(Asp38 and Asp237). This conformation mimics the expected transition state 
of the enzyme-substrate reaction. The binding of the inhibitor to the enzyme 
does not produce large distortions of the active site. No domain movement 
was observed in the complex compared to the native enzyme structure. 
However, the surface flap region (residues 82 to 88) undergoes a 
conformational change. It moves toward the inhibitor and becomes more rigid 
due to the formation of hydrogen bonds with the inhibitor. Opposite to the 
surface flap at the active site, a surface loop (residues 323 to 328) also 
undergoes a conformation change. It moves about 1 to 1.5 A towards the 
N-terminus of the inhibitor pepstatin A. Comparison of 6-factors of the two 
domains suggests that the C-terminal domain becomes more rigid in the 
complex than it is in the native structure. 
4.4 Future perspectives 
The crystal structures of RMP and its pepstatin A complex have been 
determined at 2.1 5 A and 2.7 A, respectively. Because of the relatively low 
resolution of the complex structure, no solvent molecules were added to the 
structure. It would be appropriate to extend the RMP-pepstatin A complex 
structure to higher resolution. A high resolution structure would certainly 
provide a more accurate description of the active site in the complex. Water 
molecules should be located so that we could know whether any water 
molecules are conserved in the aspartic proteinase-pepstatin A complexes, 
and possibly determine their biological functions in the proteolysis process. 
In section 3.2.5, it was proposed that the electrostatic potential at the 
active site determines the optimal pH of activity for each aspartic proteinases. 
The active site electrostatic potentials of the hypothetical mutants Asp303Ala 
chymosin b, Ala317Asp renin and Glul9Ala RMP were calculated. It is 
important to carry out the mutagenesis studies, determine the structures and 
measure the pH optima for these mutants to decide if the hypothesis can be 
validated. 
In section 3.2.6, the relationship between attached carbohydrate 
moieties and the thermal stability of RMP was discussed. A new hypothesis 
to explain how carbohydrate moieties confer glycoproteins with high thermal 
stability was proposed. The content ot jlstructure in RMP decreased with the 
prolonged oxidation. Therefore, structural studies of this oxidized RMP 
molecule should be carried out to find out how the RMP molecule has 
changed due to oxidation, and to determine the reason for the decrease of the 
enzyme activity and the relation between the carbohydrate moieties and the 
enzyme activity. Mutagenesis studies of MPP, an RMP analogue, by 
Yamashita et a/. (1994) show that substitution of Gly186 by various other 
amino acids decreases the thermal stability of MPP. The main chain torsion 
angles (#, I+Y) of Gly186 are in a region that is not allowed for the non-glycine 
residues in the Ramachandran plot. Therefore, it is appropriate to carry out 
mutagenesis studies of RMP and determine some of the structures of the 
mutants. From such studies, it should be possible to determine how this 
single residue Gly186 can cause such a large change in thermal stability and 
whether this residue can cause any conformational change of the 
carbohydrate moiety at Asn 1 88. 
From the structural comparison studies in Section 3.2.7, it is apparent 
that RMP and MPP diverged from other aspartic proteinases at an early stage 
of evolution and form a sub-family of aspartic proteinases. The molecular 
evolution of aspartic proteinases should be studied, especially the evolution of 
the substrate binding site. HIV proteinases may develop resistance to the 
inhibitors designed thus far. Therefore, substrate-binding site evolution 
studies might provide a guideline for the synthesis of more potent HIV 
inhibitors. A potent inhibitor, which is resistant to HIV mutations, might be a 
great breakthrough in the treatment of AIDS. 
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